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ABSTRACT OF THE DISSERTATION
QUANTITATIVE YTTRIUM-90 BREMSSTRAHLUNG SPECT/CT AND PET/CT
STUDY FOR 3D DOSIMETRY IN RADIOMICROSPHERE THERAPY
by
Senait Aknaw Debebe
Florida International University, 2017
Miami, Florida
Professor Anthony J. McGoron, Major Professor
Liver cancer ranks the third most common cause of cancer related mortality worldwide.
Radiomicrosphere therapy (RMT), a form of radiation therapy, involves administration of Yttrium90 (90Y) microspheres to the liver via the hepatic artery.

90

Y microspheres bremsstrahlung

SPECT/CT or PET/CT imaging could potentially identify an extrahepatic uptake. An early
detection of such an uptake, thus, could initiate preventative measures early on. However, the
quantitative accuracy of bremsstrahlung SPECT/CT images is limited by the wide and continuous
energy spectrum of 90Y bremsstrahlung photons. 90Y PET/CT imaging is also possible but limited
by the extremely small internal pair production decay. These limitation lead to inaccurate
quantitation of microsphere biodistribution especially in small tumors.
SPECT/CT and PET/CT acquisition of a Jasczak phantom with eight spherical inserts filled
with

90

Y3Cl solution were performed to measure the quantitative accuracy of the two imaging

modalities.

90

Y microsphere SPECT/CT data of 17 patients who underwent RMT for primary or

metastatic liver cancer were acquired. Technetium-99m macroaggregated albumin (99mTc-MAA)
SPECT/CT scans were also collected, but available for only twelve of the patients. SPECT/CT
images from phantoms were used to determine the optimal iteration number for the iterative spatial
resolution recovery algorithm. Methods for image based calculation of calibration factors for

v

activity estimation from the patient and phantom

90

Y bremsstrahlung SPECT/CT images were

developed. Tumor areas were segmented using an active contour method. The 99mTc-MAA and 90Y
microsphere SPECT/CT images were co-registered a priori for correlation analysis. Comparison
of uptake on

99m

Tc-MAA and 90Y microsphere SPECT/CT images was assessed using tumor to

healthy liver ratios. Furthermore, a three dimensional absorbed dose estimation algorithm was
developed using the voxel S-value method. Absorbed doses within the tumor and healthy part of
the liver were investigated for correlation with administered activity.
Improvement in contrast to noise ratio and contrast recovery coefficients (QH) on patient
and phantom 90Y bremsstrahlung SPECT/CT images as well as PET/CT images were achieved.
Total activity estimations in liver and phantom gave mean percent errors of -4 ± 12% and -23 ±
41% for patient and phantom SPECT/CT studies. The pre and post-treatment images showed
significant correlation (r = 0.9, p < 0.05) with mean TLR of 9.2 ± 9.4 and 5.0 ± 2.2 on 99mTc-MAA
and 90Y microspheres SPECT/CT respectively. The correlation between the administered activity
and tumor absorbed dose was weak (r = 0.5, p > 0.05), however, healthy liver absorbed dose
increased with administered activity (r = 0.8, p < 0.05).
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Chapter 1: Introduction
Radiomicrosphere therapy (RMT) using Yttrium-90 (90Y) microspheres is an effective
liver-directed therapy for treating primary or metastatic liver cancer (1,2). The general procedure
and the schematic of the steps are shown in Fig. 1 (I) and (II). The technique used in RMT entails
the delivery of 90Y microspheres into the hepatic artery to obtain a degree of selective uptake into
the hepatic tumors by virtue of their predominant hepatic arterial supply, as opposed to the
predominant portal venous supply to the normal liver as reported previously (3). 90Y has a relatively
long  range (mean = 2.5 mm, max = 12 mm) with minor irradiation of small tumors as these
tumors won’t be able to absorb all the emitted electrons, but irradiates more uniformly larger tumors
(≥ 34mm) that often display heterogeneous perfusion. There are currently two types of
commercially available

90

Y microspheres used in RMT: microspheres made of glass (Thera-

Sphere) and resin (SIR-Spheres). In the glass microspheres, 90Y is an integral constituent of the
insoluble and non-biodegradable glass microspheres with diameter of each microsphere 20-30µm.
The resin microspheres have diameter 20-40 µm where 90Y is incorporated into the resin matrix
where it is immobilized to the microspheres (4). 90Y microspheres are not metabolized, degraded
or excreted but remain in the organ as a permanent implant (2).
In RMT, delivery of the radioisotope containing beads or microsphere is not meant to be
occlusive to the arteries, unlike chemoembolization where the purpose is both to deliver high
concentration of chemotherapy as well as slow (or stop) arterial flow to malignant tissues. The
primary goal of RMT treatment is killing of tumors due to radiation; ischemia from occlusion of
the artery is not desired since radiation therapy is less effective in hypoxic tissues, thus hepatic
arterial flow in RMT is maintained (3). As a result, patient candidates for RMT treatment can also
be those thought to be poor candidates for chemoembolization due to the fact that they are at high
risk of mortality owing to acute liver necrosis from combined portal vein thrombosis and hepatic

1

arterial occlusion. The biodistribution of

90

Y after treatment is currently assessed through

90

Y

bremsstrahlung SPECT/CT imaging (5-7).

Figure 1:(I) RMT procedure: (A) introduction of a catheter into the femoral artery, (B) injection
of microspheres, (C) liver vasculature (8). (II) Process diagram of RMT.

Technetium-99m macroaggregated albumin (99mTc-MAA) scanning is performed prior to
RMT as a surrogate for

90

Y microspheres. In pre-RMT planning,

99m

Tc-MAA planar and

SPECT/CT imaging is used to measure the percentage of particles that shunt to the lungs (lung
shunt fraction, LSF), to assess any extrahepatic particle deposition, and to calculate the tumor to
normal liver ratio (1,9). However, due to the significant differences in size and shape of the MAA

2

and the microspheres (99mTc-MAA: ~10-50 μm and 90Y microspheres: 20-40 μm), and the position
of the catheter tip between the

99m

Tc-MAA and

90

Y microsphere procedures, differences in the

distribution between the two procedures may result. Multiple authors have demonstrated
discrepancies of uptake and distribution between

99m

Tc-MAA and 90Y microsphere SPECT/CT,

questioning the predictive accuracy of 99mTc-MAA for RMT (9,10).

Figure 2: Various positions of a catheter tip during pretreatment stage and associated with
unintended distribution (11).

Post RMT imaging of the

90

Y could potentially identify extrahepatic uptake. An early

detection of such uptake, thus, could lead to the initiation of preventative measures early on (6).
The tumor and liver dose estimates obtained from 90Y microsphere bremsstrahlung SPECT/CT or
PET/CT imaging could be correlated with tumor response and liver toxicity clinical data. The major
problem with 90Y bremsstrahlung imaging is the lack of a pronounced photopeak energy due to the
continuous and broad energy spectrum of bremsstrahlung photons resulting it poor image quality.
As a result, various studies based on phantoms and Monte Carlo (MC) simulations have
recommended appropriate energy windows in accordance with the collimator used (12-15). It has
been shown, often with phantom studies, the incorporation of MC simulation to clinical images can
provide optimally accurate bremsstrahlung images by compensating for attenuated and scattered
photons through correction for attenuation scatter and collimator-detector response (14-16).
Alternately, studies have demonstrated the feasibility of

90

Y microsphere PET/CT imaging

excelling in contrast and resolution compared to bremsstrahlung SPECT/CT (17,18). A recent study

3

by Yue et al. (18) concluded that both modalities are comparable for post-treatment dosimetry
estimation if appropriate reconstruction for 90Y bremsstrahlung SPECT/CT is applied. However,
an appropriate reconstruction method requires incorporation of MC simulation in

90

Y

bremsstrahlung SPECT/CT for quantitative improvement. But the MC based approach is not
commercially available and is not easily applied for clinical implementation (19,20). Siman el al.
(19) recently developed a practical imaging protocol employing background compensation for 90Y
microsphere SPECT/CT imaging as an alternative to the MC method. The authors assert that their
method doesn’t address the main image degrading factors in 90Y bremsstrahlung SPECT imaging,
such as object scatter, septal penetration, and backscatter; nonetheless, they stated an improvement
in recovery coefficient from 39% to 90% in a 37 mm sphere in a 10 mm volume of interest.
The present dissertation addresses the development and application of post-reconstruction
techniques to improve the quality and quantitation of

90

Y SPECT/CT and PET/CT images.

Different imaging windows, collimators, acquisition times and reconstruction algorithms were
investigated with a phantom study. Issues related to calibration factor for activity estimation from
patient and phantom

90

Y SPECT/CT images as well as PET/CT images were addressed. Co-

registration methods for better alignment of

99m

Tc-MAA and

90

Y SPECT/CT images were

identified and evaluated. Subsequently, the correlation of the uptake pattern on the improved 90Y
microsphere SPECT post-therapy images and on pre-treatment

99m

Tc-MAA SPECT images was

evaluated. A three-dimensional (3D) absorbed dose estimation (dosimetry) algorithm using the
voxel S-value method was developed. Thus, the association between administered activity and liver
and tumor dosimetry in the patient study was analyzed.
1.1

Objective, specific aims and hypotheses

The overall objective is to achieve a quantitative improvement of 90Y bremsstrahlung SPECT and
PET images and a subsequent comparison of uptake pattern between pretreatment 99mTc-MAA and

4

improved 90Y bremsstrahlung SPECT images, and finally to develop a 3D dosimetry method for
estimation of 90Y absorbed dose in tumor and healthy liver.
This objective was accomplished by addressing the following specific aims:
1.1.1

Specific Aim 1

Improve the quantitative quality of 90Y bremsstrahlung SPECT and PET images through evaluation
of various imaging energy windows, collimator types, acquisition times, reconstruction algorithms
and the development of a post-reconstruction image improvement algorithm.
The outcome of this aim provided improved images for the subsequent analyses. This aim included
estimation of the camera point spread function (PSF).
1.1.2

Specific Aim 2

Compare the uptake pattern in pre-treatment

99m

Tc-MAA and post-treatment

90

Y microsphere

SPECT/CT images.
The outcome of this aim was to assess the degree of accuracy by which 99mTc-MAA SPEC/CT can
predict treatment outcome. This aim includes co-registration of 99mTc-MAA and 90Y microsphere
SPECT/CT images.
1.1.3

Specific Aim 3

Develop an algorithm using the voxel S value method to transform 90Y bremsstrahlung SPECT and
PET image pixel values (counts per second, cps) to absorbed dose values (Gy) and generate
absorbed dose rate distribution at the voxel level.
The outcome of this aim was to generate images with absorbed dose values at the voxel level. This
aim includes calculation of the camera calibration factor (sensitivity). This aim also includes
analysis of the correlation between administered activity and absorbed doses in tumorous and
healthy liver.

5

Chapter 2: Background
2.2 Nuclear Medicine Imaging Modalities in Liver Cancer Management
There are various imaging modalities used in the diagnosis, treatment planning and
evaluation of liver cancer: ultrasound, MRI, CT, planar nuclear imaging, SPECT and PET. Among
which planar, SPECT and PET fall under nuclear medicine imaging, which the dissertation will be
focusing on. CT, typically used as a diagnostic tool, is also incorporated into the dual imaging
modalities, SPECT/CT and PET/CT, and used for correcting image degrading factors. Thus, it is
discussed in conjunction with the dual modalities.
2.2.1 Gamma/ planar imaging
The Anger camera, named for its inventor Hal O Anger, or gamma/planar/scintillation
camera is the most commonly used static imaging device in nuclear medicine, and was
commercialized as early as mid-1960’s (21). The major components of a gamma camera are a
collimator, a large area NaI(TI) scintillation crystal, a light guide, and an array of photomultiplier
tubes (PMT). The basic principle how the camera works is shown in Fig 3. The collimator consists
of a very large lead plate with many small holes through it. Only those photons that are
perpendicular to the collimator plane (or parallel to the axes of the holes) can pass cleanly through
the holes to be absorbed by the scintillation crystal. There are different kinds of collimators used in
clinical practice, depending on the type of radionuclide imaged (Table 1). The scintillation crystal
is commonly made from sodium iodide with a small amount of thallium impurity, NaI(TI). The
crystal emits light photons whenever it absorbs a gamma ray, where the intensity of the light is
directly proportional to the energy of the gamma ray. The purpose of the PMT is to act as a
transducer by changing the visible light from the crystal to electric current, which is directly
proportional to the amount of light. The current pulses then go through a preamplifier before being
sent for further processing. The outputs of the PMT are converted into a three-dimensional signal
after processing. Two of the signals (X and Y) contain the spatial location of the scintillation while
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the energy deposited in the crystal is represented in Z to portray a 3D distribution of a radioactive
decay as a 2D image with no depth information. Due to this and the selectivity of the collimator in
passing gamma rays, the resolution of a gamma camera is between 6.4 – 12.6 mm, with
considerable loss of contrast and sensitivity (0.1%, so that 99.9% photons are not detected) (22).
The preferred emission energies of gamma () rays ranges from 80 to 500 keV with 20-25%
window width from the photopeak (21,23). Gamma rays of these energies can sufficiently penetrate
body tissues to be detected from internal organs, and can be stopped efficiently by dense
scintillators.

Figure 3: Basic components of gamma camera (23).
Table 1: Collimator specification at 10cm from collimator face (22) .
Collimator type

Low-energy highresolution (LEHR)
Low-energy
general purpose
(LEGP)
Medium-energy
general purpose
(MEGP)
High-energy
general purpose
(HEGP)

Hole
Diameter
(mm)
1.4

Septal
Thickness
(mm)
0.152

Hole
Length
(mm)
32.8

Resolution
(mm)

Sensitivity
(cps/MBq)

Energy
(keV)

6.4

91

140

1.4

0.180

24.7

8.3

149

140

2.95

1.143

48.0

10.8

140

280

3.81

1.727

60.0

12.6

61

360
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In liver cancer management, planar imaging (Fig. 4) is used in the ‘mapping’ phase where
diagnostic angiography and intra-arterial administration of 99mTc-MAA microspheres is performed
that mimic the distribution of 90Y microspheres. Diagnostic angiography is used to identify arteries
arising from the hepatic artery to determine if coil embolization is necessary and to select the best
catheter position for tumor targeting.

99m

Tc-MAA planar imaging is done for determining the

percentage of particles that shunt to the lungs (lung shunt fraction, LSF) which might require
adjustment of the amount of 90Y microsphere administered to reduce potential damage to the lungs.
𝐿𝑆𝐹 =

𝐿𝑢𝑛𝑔 𝑐𝑜𝑢𝑛𝑡𝑠
𝐿𝑢𝑛𝑔 𝑐𝑜𝑢𝑛𝑡𝑠+ 𝑙𝑖𝑣𝑒𝑟 𝑐𝑜𝑢𝑛𝑡𝑠

1

Figure 4: Example of planar images with ROIs drawn over the anterior (a) and posterior (b) of
lungs and liver images to determine the LSF (24).
2.2.2 Single photon emission tomography (SPECT)
Nowadays gamma cameras with SPECT capability of dual-head detectors is employed in
most clinical centers. SPECT imaging overcomes the drawbacks of planar imaging by providing
3D information with depth information by collecting views from different directions. The total
rotation of a SPECT gantry around a patient is usually 180 о or 360 о, and the total number of
projections may vary from 64 to 128. Although data acquired over an arc of 180 о are sufficient for
tomographic reconstruction in SPECT, there are advantages in terms of resolution uniformity and
correction for γ-rays attenuation in acquiring data over a full 360 degree arc. The acquisition pixel

8

matrix should be of the same order as the number of projections to avoid the appearance of artifacts,
thus clinical SPECT images are reconstructed in a matrix of 64x64 or 128x128 pixels. Cross
sectional images are produced for all axial locations (slices) covered by the field of view (FOV) of
the gamma camera, resulting in a stack of contiguous 2D images that form a 3D image volume.
The common methods to reconstruct 3D images from planar images are the filtered back-projection
(FBP) and iterative methods such as maximum likelihood expectation maximization (MEM).
Mathematical filters are used to obtain an image of adequate quality but since filters change raw
images, the choice of a particular filter and its parameters depends on the physical characteristics
of the organ under study. Several types of artifacts may appear using the SPECT techniques that
are related to instrumentation, patient, study acquisition or data processing.
A SPECT/CT system consists of a single unit that integrates SPECT and CT (Fig. 5),
allowing data acquisition of each modality in a single patient study. The CT images are used both
for attenuation correction and for anatomical location. When CT is used for SPECT attenuation
correction, the resolution of CT data is reduced to match the SPECT. In addition, since the effective
energy of the x-ray beam is about 70 keV and the attenuation varies with energy, the CT attenuation
map is converted to the radionuclide photon energy used in SPECT (for example, about 140keV
when 99mTc is used). The total time of a SPECT/CT study is significantly reduced because of the
fast acquisition speed of CT compared to SPECT. The anatomical images acquired with CT can be
merged with the SPECT emission images to provide functional anatomical maps for precise
localization of radiotracer uptake. The hybrid technique allows precise localization of primary
tumors and evaluation of extent of disease. In hybrid SPECT/CT, SPECT is performed in a 360 о
rotation, consisting of 60 projections 6 о apart in a matrix of 128x128 (25).
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X—ray generator

Gamma detector 1
Detector 1

Detector 1

CT

Patient table

Gamma detector 2

X—ray detector

Figure 5: SPECT/CT camera (left) and its schematic (right).
The fundamental relationship between the projection space and the image (object) space in
SPECT image formation (Fig. 6) is given as:
𝑝(𝑠, 𝜃) = ∬ 𝑓(𝑥, 𝑦)𝛿(𝑥𝑐𝑜𝑠𝜃 + 𝑦𝑠𝑖𝑛𝜃 − 𝑠)𝑑𝑥𝑑𝑦

2

Where f(x,y) is object representation in image space, δ (..) is the Dirac delta function, and g(r,ϴ)
is the projection data along ϴ and r of projection angle and line respectively. In SPECT however,
this relationship is not linear due to image degrading factors discussed below.

Figure 6: SPECT image formation (left) and 2D image reconstruction (right) (26).
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Image degrading factors in SPECT
Photon attenuation and scatter
There are five types of x- and γ-ray interactions with matter: Compton scattering,
photoelectric effect, pair production, Rayleigh (coherent) scattering and photonuclear interactions.
The first three interactions are the most important as they result in the transfer of energy to electrons
which then impart the energy to matter. But the importance of these interactions depends both on
the photon quantum energy (Eγ = hv) and the atomic number Z of the absorbing medium (Fig 7).
Rayleigh scattering is elastic scattering where the photon is redirected with no energy loss and
photonuclear interactions are only significant for high energy photons (E > >MeV) where there is
production of neutrons. The major interaction that occur in SPECT imaging are photoelectric and
Compton scattering due to the range of photon energies detected (80 – 500 keV). Photoelectric
effect is dominant at lower energies and mostly occurs in high Z media such as lead while the
Compton scattering occurs at medium energy and is dominant in low Z media such as human tissue,
water, etc. Each of these effects contribute to photon attenuation and scatter in SPECT. Attenuation
results from absorption by the photoelectric effect, Compton scattering, and pair production at a
higher energy depending on the photon energy and thickness of the absorber (Eqn. 3). Scattering
in SPECT is mainly due to Compton scatter where the photon is deflected at an angle ϴ (0 - 180°)
from its original direction with a reduced energy due to its interaction with an outer shell electron
of the absorber atom (Eqn. 4). For ϴ = 180°, backscattering collision results.
𝐼𝑡 = √𝐼1 ×𝐼2 = √[(〖𝐼01 ×𝐼02 )𝑒〗−𝜇(𝑎+𝑏)
𝐸𝑠𝑐 =
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= √𝐼01 ×𝐼02 𝑒 −𝜇(𝐷/2)

𝐸0
𝐸
[1+ 02
𝑚𝑐

(1−𝑐𝑜𝑠𝜃)]

3

4

I01 and I02 are the initial photons, a and b are source depths, It is the total attenuated photons
transmitted from the two detectors, μ is the linear attenuation coefficient and D = a + b, thickness
of the absorber, Esc and E0 are the scattered and initial photon energies respectively.

Figure 7: The three major types of photon interactions in SPECT(27).
Collimator detector response
Collimator detector response (CDR) is the response of the camera from a point source
activity where the shape of the response determines the resolution in SPECT (28,29). CDR varies
with distance from the detector (Fig. 8) causing different blurring at different distances but CDR is
spatially invariant at a constant distance, d, from the detector surface. CDR in SPECT has four
components: intrinsic response, geometrical response, septal penetration and septal scatter. The
last two components are particularly problematic for high energy emitters such

90

Y causing

additional loss of image contrast due to degradation of spatial resolution. The intrinsic response is
the response of the scintillation camera, excluding the collimator, to a pencil beam of radiation.
Intrinsic response is dependent on the energy of the incident photon, the energy window used, and
the thickness and composition of the crystal and it represents the efficiency of the crystal in
detecting photons. The geometric response is the total collimator response function that represents
the distribution of the detected photons that travel through the collimator hole without interacting
or passing through the collimator septa and is the easiest to treat theoretically. The general form of
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the collimator-detector response function is given in Eqn. 5. Geometric collimator resolution (Rc)
is given by Eqn. 6.
𝑑 (𝑠, 𝐷) = 𝑖(𝑠)×(𝑔𝑐 (𝑠, 𝐷) + 𝑝𝑠 (𝑠, 𝐷) + 𝑠𝑠 (𝑠, 𝐷))
𝑔𝑐 = 𝑑

(𝑙𝑒 +𝑏)

5
6

𝑙𝑒

Figure 8: Profile of a parallel hole collimator for a point source (23).
Where D and b are the distance from the radiation source to the collimator, i(s) is the intrinsic point
response function, gc(s,D), ps(s,D), and ss(t,D) are the collimator geometric, septal penetration and
septal scatter correction respectively, and d is the diameter and le = l - 2μ-1 the effective length of
the collimator holes. For simplicity, the septal penetration and scatter are neglected giving the
system resolution (Rs) of SPECT camera as the combined effect of the intrinsic (Ri) and geometric
(Rc) resolutions:

𝑅𝑠 = √𝑅𝑖2 + 𝑅𝑐2
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As a result of these image degrading factors in SPECT, the projection data in the image formation
given by Eqn. 8 will be modified to include these effects as follows:
∞

𝑡

𝑝(𝑠, 𝜃) = ∫−∞ 𝑑𝑡 ∫ 𝑑𝑠 ′ ×𝑓(𝑠 ′ , 𝑡)×𝑠𝑓(𝑠 ′ , 𝑡; 𝑠)×𝑑𝑓(𝑠 ′ − 𝑠; 𝐷 + 𝑡)× exp [− ∫𝑡 𝜇(𝑠 ′ , 𝑡 ′ )𝑑𝑡 ′ ]
𝑑
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Where s’= (su,sv), sf(s’,t;s) is the scatter response function, df is the collimator detector response,
D is the distance between the collimator and the center of rotation and z=D+t, and td is the tcoordinate of the detection plane(26). The equation is further complicated by the inclusion of 3D
collimator-detector response. The following step of image reconstruction is to find a solution of
f(s,t) from the projections described by Eqn. 8.
SPECT image reconstruction
Image reconstruction is done using mathematical algorithms to reconstruct images from
the multiple projections of detected emissions from radionuclides within a subject, known as
emission computed tomography (Fig. 6). Although the instrumentation in CT, SPECT and PET
differ, the mathematics of image reconstruction are the same. There are different techniques of
image reconstruction in tomography: simple back-projection, direct Fourier Transform, filteredback-projection and iterative reconstruction algorithms. Iterative methods such as maximum
likelihood expectation maximization (MLEM), particularly its accelerated version OSEM, offer
potential benefits that lead to better results. The pronounced property of iterative reconstruction is
that it can be modified to incorporate weights or penalties such as correction for photon
attenuation, scatter and compensation for spatial resolution losses which enables the algorithm to
be tuned for specific clinical requirements. The method is suggested for quantitative SPECT image
analysis since it allows for optimal correction of image degrading physical effects, improving
noise properties. In addition, compensation for physical limitations can be modelled in the
reconstruction process of iterative methods(30). SPECT/CT imaging in liver cancer management
is used at two stages: pretreatment 99mTc-MAA and post-treatment 90Y imaging.
99m

Tc-MAA Imaging
Technetium-99m macroaggregated albumin (99mTc-MAA) scanning using SPECT or

SPECT/CT modality is performed before 90Y RMT in order to detect activity outside of the liver
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(1). 99mTc-MAA SPECT/CT allows for an accurate volume measurement that provides a valuable
contribution to the therapeutic planning of patients with liver cancer. It can be used to determine
liver volume, and for quantitation of injected dose. In pre-RMT planning, dosimetry based on
99m

Tc-MAA SPECT/CT can be used for selection of patients and assess any potential extrahepatic

particle deposition. 99mTc-MAA SPECT/CT is also used to calculate the tumor to normal liver ratio
(TLR) (9). Based on these determined values the administered 90Y activity dose (Ainj) is calculated
from a well-defined model [Fig. 9(A)] according to the Medical Internal Radiation Dose (MIRD)
scheme, using the empirical method given by Eqn. 9 or by the body surface area (BSA) method
given by Eqn. 11 (31). The absorbed dose in the tumor, healthy liver and lungs is calculated using
Eqn. 12 where the fractional uptake is the fraction of the administered activity expected to be
deposited within the volume of interest.

A

B

Figure 9: (A) Reference anatomic model used for conventional dose calculation (32) and (B)
99m
Tc-MAA SPECT/CT scan of a patient.

15

2𝐺𝐵𝑞,
𝑖𝑓 𝑟 < 25%,
𝐴𝑖𝑛𝑗 = {2.5𝐺𝐵𝑞, 𝑖𝑓 25% < 𝑟 < 50%,
3𝐺𝐵𝑞, 𝑖𝑓 𝑟 > 50%

9

Where r = (Tumor volume/Total liver volume)*100
Max tumor counts

TLR = Average liver counts
𝐴𝑖𝑛𝑗 (𝐺𝐵𝑞) = 𝐵𝑆𝐴 − 0.2 +

𝐷𝑜𝑠𝑒 (𝐺𝑦) =

10

𝑇𝑢𝑚𝑜𝑟 𝑣𝑜𝑙𝑢𝑚𝑒
𝑇𝑢𝑚𝑜𝑟 𝑣𝑜𝑙𝑢𝑚𝑒+𝑙𝑖𝑣𝑒𝑟 𝑣𝑜𝑙𝑢𝑚𝑒
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𝐴𝑖𝑛𝑗 ×49,800 ×𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛𝑎𝑙 𝑢𝑝𝑡𝑎𝑘𝑒
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𝑀𝑎𝑠𝑠

Based on 99mTc-MAA SPECT/CT imaging patients with LSF higher than 20% or absorbed dose in
the lungs ≥ 30Gy for

90

Y resin and glass microspheres respectively are disqualified for RMT

treatment (33).
90

Y SPECT Imaging
Post-treatment

90

Y bremsstrahlung imaging is recommended by most physicians and is

currently a routine imaging procedure performed during the first 24 hrs of treatment (5-7,34). The
main reasons for post treatment imaging is to potentially identify the unexpected presence of 90Y
microspheres outside the liver which will likely cause serious complications such as ulceration and
GI tract bleeding (17,34). The number of 90Y microspheres injected is very high compared to 99mTcMAA which might lead to a more powerful embolic effect that contributes to slowing down the
blood flux or even induces transient blockade of the targeted vessels. This can significantly modify
the arterial flow, resulting in a distribution of the 90Y microspheres different to that of the

99m

Tc-

MAA (35). .90Y accumulation in organs other than liver causes serious complication due to the high
radiosensitivity of the surrounding organs. Thus early detection of extrahepatic activity will help
in preventing development of more serious problems through aggressive pain management such as
surgery, angioplasty or stent, supportive management, etc. based on the symptoms developed
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(17,36). Dosimetry of tumorous and non-tumorous tissues from post-treatment imaging could be

correlated with tumor response and liver toxicity. The major problem in bremsstrahlung
SPECT imaging is the lack of pronounced photopeak energy due to the continuous and broad
energy spectrum of bremsstrahlung photons (Fig. 10). The absence of a photopeak energy window
makes it difficult to achieve window based scatter rejection, scatter correction, and attenuation
correction which all contribute to low quality bremsstrahlung SPECT images (17). The difficulty
to separate the counts on the image that come from primary photons, from those that have been
scattered, penetrated the collimator septa, or back-scatter from the camera housing and photomultiplying tubes make it very complex to achieve scatter correction. At any energy window, the
ratio of primary bremsstrahlung to the total number of photons detected is < 15%, with the highest
primary fraction occurring between 80-180 keV (37-39). Despite the wide range of energies imaged
during bremsstrahlung SPECT, it is agreed upon by authors to use a single effective attenuation
coefficient for attenuation correction (40,41). However, this would result in discrepancy of the
actual value of the attenuation coefficient and the reconstruction technique used. It has been shown,
often in conjunction with phantom studies, that Monte Carlo simulations help to optimize the
accuracy of bremsstrahlung images by enabling correction for attenuation, scatter and collimatordetector response with error less than 11% for sphere volumes about 100 ml and larger (14,16,42).
Proper attenuation correction requires an attenuation map specific to the object being imaged,
patient specific in a clinical case. To achieve dosimetry based on the image at hand, i.e. patient
specific dosimetry, applying attenuation correction on the image is one of the necessities (30).
Photon attenuation correction is especially critical in the clinical setting where thickness of tissues
varies for different regions of the patients’ anatomy (26).
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Figure 10: Schematic representation of the energy levels (43) and energy spectrum of 90Y(7).

Determining an optimal energy window where these effects are minimized is critical for
accurate dosimetry. As a result different acquisition energy windows have been recommended by
many authors (12-15). In a phantom study and Monte Carlo simulation Minarik et al. (14) suggested
that adequate image quality can be obtained in the 105- 195keV energy window, and it was stated
that a window with a lower limit below ~80keV will include counts for characteristics X-ray
photons produced in the lead collimator. Ito et al. (13) used three energy windows centered at
75keV ± 25% (57-94keV), 120keV ± 15% (102-138keV) and 185keV ± 25% (139-232keV) in a
phantom study. They found that bremsstrahlung SPECT/CT acquisition centered at the 120keV
energy window resulted in the highest spatial resolution. A wide energy window (55-285keV) with
medium-energy collimation was used by Shen et al. (12) to optimize sensitivity, but this window
results in loss of spatial resolution or requires high-energy collimator and restoration filters (40).
In clinical practice, image acquisition centered on 90 keV ± 15% is currently a standard protocol.
In addition to choosing the optimal energy window for imaging bremsstrahlung photons, various
pre and post reconstruction optimization efforts have been done to improve bremsstrahlung image
quality. The same groups who studied the various acquisition windows have investigated various
scatter correction techniques (14,15). Ahmadzadehfar et al. (34) addressed the usefulness and
significance of bremsstrahlung SPECT/CT imaging for post-treatment dosimetry. In the
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manuscript, it is shown that 90Y bremsstrahlung imaging is feasible, despite scattering and other
image degrading artifacts, and it was stated that this imaging could help to appropriately and timely
manage patient wellbeing if extrahepatic tracer deposition occurs. The study showed that detection
of extrahepatic activity with the post-treatment scan predicted GI ulcers with a sensitivity of 87%
and a specificity of 100%. These predictions help form decisions for an appropriate and timely
management strategy when extrahepatic deposition occurs. Minarik et al. (14) also suggested that
with proper and accurate dosimetry based on quantitative bremsstrahlung imaging, it is possible to
find the relationship between the real uptake relative to the estimate based on pre-treatment tracer
to be able to modify a therapy for future treatment and to assess the treatment efficiency.
2.2.3 Positron emission tomography (PET)
PET imaging is used with positron-emitting radionuclides. PET detectors detect the ‘backto-back’ two annihilation photons that are produced when a positron interacts with an ordinary
electron (44,45). The photons have identical energy (511 keV) and are emitted simultaneously, in
180-degrees opposing directions. The volume from which these pairs of annihilation photons were
emitted can be defined by a technique called annihilation coincidence detection. Because the point
of annihilation is very close to the point of positron emission, this gives a good indication of where
the radioactive atom was in the body. As a result, PET scanners don’t have mechanical collimation
to localize radioactive decay as in SPECT, and hence no limit to the field of view. PET scanners
instead use electronic collimation that depends on the line of response that passes through the point
of annihilation joining the detected photons (Fig. 11 & 12). PET scanners are designed and
optimized for imaging all positron-emitting radionuclides at this single energy range (511keV). By
using computed tomography techniques to measure the total radioactivity along the lines that pass
at many different angles through the object, two-dimensional images that reflect the concentration
of the positron emitting radionuclide in tissues can be reconstructed. The energy of annihilation
photons fall in the gamma ray electromagnetic spectrum and the properties of annihilation photons
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are identical to a 511 keV gamma rays, as a result the terms photons and gamma-rays are often
used interchangeably when referring to the annihilation photons (46). However, the origins of the
two photons are different since annihilation photons do not come from the nucleus. Time of flight
(TOF) PET is a technique used to determine the location where the annihilation originated along
the line of response (LOR). The time difference between the arrivals of the two annihilation photons
at the opposite detectors is measured in TOF PET where annihilation events are localized more
accurately in along the line of response (Fig. 11). If the difference in arrival times of photons is Δt,
the location of the annihilation event with respect to the midpoint between detectors is given by
Eqn. 13.

Figure 11: Equal probability assigned to all the pixels along LOR in non-TOF PET (a) and localized
counts along the LOR with TOF PET (b) (47).

𝛥𝑑 =

Δ𝑡 ×𝑐
2
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Figure 12: The process of positron-electron annihilation and detection of the annihilation photons
(left) and illustration of PET/CT scanner components (48) (right).
Image degrading factors in PET
The main image degrading factors in PET include attenuation, random coincidences and
scatter coincidences. As is the case with SPECT, photoelectric effect and Compton scattering are
the two major mechanisms by which 511 keV photons interact with matter and which give rise to
photon attenuation in PET. Attenuation correction in PET is much more accurate compared to
SPECT since the correction is independent of the location of the source in the body. With the
inclusion of CT with PET, attenuation correction is achieved with the transmission information
from CT although it requires a scaling before it can used since the CT scan is acquired at lower
photon energy compared to the 511 keV photons in PET. The CT scan will also provide anatomical
localization of PET images giving a better tumor localization compared to PET alone. Random
coincidence events in PET occur when two photons originating from different positron decays hit
the detector ring within a narrow timing window. Scattered coincidence occurs when one of the
photons from an annihilation event undergoes Compton scattering, which can usually be corrected
by using energy discrimination.
Tumors are known for their greater metabolic activity accompanied by a greater glucose
uptake relative to the surrounding normal tissue (49). Several tracers for glucose metabolism have
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been investigated in PET imaging. Fluorine-18-fluorodeoxyglucose positron emission tomography
(18F- FDG-PET) is the second most used modality in liver cancer imaging because of its
significance in the evaluation of extrahepatic disease (50).
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F-FDG is a glucose analogue with a

biological half-life of 110 minutes, thus accumulation of FDG in tissue is proportional to glucose
utilization (51). Greater glucose uptake can be identified with FDG PET which allows for the
identification of a tumor foci. However, any focal area of hypermetabolism can give false-positive
results (52). PET has the ability to detect liver metastases comparable to MRI and is useful for
detecting extrahepatic metastatic disease (53). The limitation of FDG PET is in detecting tumors
smaller than 1 cm (49,54). However, the role of FDG PET/CT in the evaluation and characterization
of liver metastases is uncertain due to the heterogeneous uptake of FDG which makes it difficult to
exclude the presence of small metastases (49,50).
In 2004, a study showed that 90Y generates pair production at 511 keV that can be detected
with a PET camera (55). Various studies have since then demonstrated the feasibility of

90

Y

microsphere PET/CT imaging as an alternative to 90Y bremsstrahlung SPECT/CT imaging (17,18).
90

Y emits 32 positrons per second per MBq (32 per 1,000,000 decays) with a maximum energy of

758 keV (56). Though the rate of pair production is very small, there is a detectable peak of 511
keV photons surpassing the continuous spectrum of bremsstrahlung photons (Fig 13). Despite the
very low positron abundance, various studies have shown 90Y PET/CT images excelling in contrast
and resolution compared to bremsstrahlung SPECT/CT (12,17,18). Elschot et al. (17) compared
90

Y PET/CT and SPECT/CT in a phantom study with simulated activities. The PET/CT was

performed with TOF capability and the image reconstruction included the PSF of the camera while
the SPECT/CT was performed using a HEGP collimator with energy window centered at 150 ±
30% and images were reconstructed with OSEM including the PSF of the detector. The study found
that PET estimates activities more accurately than SPECT, in addition, higher contrast recovery
coefficient was found on the PET images. The pitfall of the study is that it was a simulated study
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that doesn’t represent an actual clinical scenario with acquisition time of 60 min PET and 120 min
for the SPECT, which gives the PET camera the advantage of collecting more annihilation events.
A recent study by Yue et al. (18) investigated patient post-treatment

90

Y PET/CT and

bremsstrahlung SPECT/CT where the two scans were performed on the same day. PET/CT was
done for 30 min per one bed position and the SPECT/CT was done on HEGP collimator with
acquisition energy between 100-300 keV. Even though the PET/CT was performed without TOF
and coincidence correction capability, the authors concluded that the total activity estimate in the
liver is comparable between the two modalities, but PET/CT overestimated 90Y activity in regions
with low or no activity. This study lacks correction for prompt coincidence between annihilation
and bremsstrahlung photon 90Y imaging. Also, with non TOF capability of PET, the overestimation
of photons is inevitable. Thus the total estimate inside the liver could give a satisfactory result, but
dosimetry estimation inside tumor and healthy liver region will be compromised as the photons are
not spatially corrected, resulting in loss of accuracy.

Figure 13: Positron fraction over the continuous bremsstrahlung spectrum as measured by
germanium spectrometer (55).
Chapter 3: Framework for Experimental Setup, Data Acquisition and Data Collection
3.1 Introduction
A

90

Y imaging study, although technically possible, given the inherit characteristics of

bremsstrahlung photons current use of the post -RMT bremsstrahlung SPECT/CT is limited to the
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qualitative assessment of the final location of the microspheres (33). Though various authors have
come to agreement with the optimal choice of collimator type and acquisition energy window, these
choices are not clinically employed as

90

Y imaging protocol in many centers. Currently most

clinical practices follow the American Association of Physicists in Medicine (AAPM)
recommendation for post-treatment 90Y bremsstrahlung SPECT/CT imaging, which recommends
the use of medium-energy collimation and energy window centered at 80 ± 15% keV (68 – 92 keV)
(33).
The choice and inclusion criteria for conducting patient research of 90Y bremsstrahlung
SPECT/CT imaging varies from one author to the other (Table 2). Patient studies who had whole
liver or single lobe treatment might present similar results due to related nomenclatures which
requires a cautious interpretation of the presented results. As to whether the whole liver or a single
lobe is treated, consistency in the imaging protocol is exceedingly important.
90

Y phantom studies are usually done with activity much lower than the actual patient

administered activities with great variability across studies, different sphere-to-background ratio,
different background concentration and different acquisition time (Table 3). But most studies try
to replicate the sphere to background ratios comparable to tumor to healthy liver activity ratios
encountered in clinical studies (Table 3 & 4). The fact that the activities inside the spheres and
phantoms are much lower could result in a reduced statistical count in the reconstructed images
compromising the accuracy of measured values.
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Table 2: Summary of patient 90Y bremsstrahlung SPECT/CT studies.
Author

No of
patients

Whole vs. single
lobular
treatment

Total liver
size (ml)

Tumor sizes
(treated
volume) (ml)

40

Whole

15 – 984.2

36

Single

898.73982.0
NA

Tumor to liver
ratio based on
99m
Tc-MAA
SPECT/CT
2.8-15.4

187 (mean)

7.2

5

Whole (4)

1230-3050

20-383

NA

502

NA

NA

1.65-2.61

15

Whole (201) and
single (301)
Single

NA

397-2262

NA

30

NA

NA

NA

NA

Gulec et al.
(31)
Garin et al.
(9)
Elschot et
al. (17)
Ilhan et al.
(10)
Yue et al.
(18)
Siman et
al. (19)

Table 3: Summary of 90Y bremsstrahlung SPECT/CT phantom study setups
Autho
r

Phanto
m

Minar
ik et
al.
(14)

Elliptica
l

Rong
et al.
(15)

# of
spheres

Sphere
diamete
r (mm)

Spher
e to
bkg.
ratio

Exp
. vs.
sim.

Acquis
ition
energy
(keV)

Collimat
or

Reconstruct
ion alg.
(iter/sub) &
compensati
on

1

60

No
backg
round
activit
y

Exp
.&
sim.

105195

HEGP

OSEM
(4/12)
scatter &
attn.

Elliptica
l

3

15, 33,
55

10:1 a,
20:1b

Exp
.&
sim.

100500c
02000d

HEGP

OSEM
(400/16)
scatter &
attn.

Elsch
ot et
al.
(17)

IEC

6

10, 13,
17, 22,
28, 37

9:1

Exp
. but
sim.
cou
nts

105195

HEGP

OSEM
(8/8) with
PSF & attn.

Siman
et al.
(19)

IEC

1

37

7.8:1

Exp
.

90125c,
310410e

MEGP

OSEM
(128/16)
bkg & attn.
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Bkg: background; Exp: Experimental; sim: simulated; iter/sub: iteration/subset; alg.: algorithm;
attn: attenuation
a

sphere to background ratio in the large and medium sphere.

b

sphere to background ratio in the small sphere.

c

multiple energy windows were used and reported the values in the table are used for the
phantom study
Table 4: Summary of PET/CT studies
Author

Phantom
type

No of
patients

Sphere
diameter(
mm)

Sphere to
bkg. ratio

Exp. vs.
sim.

TOF

Scatter
and attn.
correction

Elschot et
al. (17)

IEC

6

9:1

Corrected

NA

15

Exp, but
sim.
counts
Patient
data

TOF

Yue et al.
(18)
Willowson
et al. (57)

10, 13,
17, 22,
28, 37
NA

NonTOF

Corrected

NA

1
IEC

Attarwala
et al. (58)

NA

Martí‐
Climent et
al. (56)

Jaszczak

10

Willowson
et al. (59)

IEC

NA

Rowley et
al. (60)

IEC

10

10, 13,
17, 22,
28, 37

8:1

Exp.

TOF

Corrected

31.3,
28.1,
21.8,
16.1 13.3
10, 13,
17, 22,
28, 37

2.5

Exp.

TOF,
NonTOF

Corrected

8:1

Exp. but
sim.
counts
(7 days)
Exp. but
sim.
counts
(12 hr)

TOF,
NonTOF

Corrected

TOF

Corrected

10, 13,
17, 22,
28, 37

3.2 Materials and Methods
3.2.1 Patient study:
Patient data were acquired from Baptist Hospital of Miami as part of a retrospective study
approved by the Florida International University Institutional Review Board. Therefore, written
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patient informed consent was not sought nor documented and image data were handled
anonymously.
99m

Tc-MAA SPECT/CT imaging
All patients had undergone 99mTc-MAA SPECT/CT scan before RMT, of which twelve of

those patients were used for comparison of tumor to liver ratios for our study as the

99m

Tc-MAA

SPECT/CT data from the remaining seven patients had been transferred to a different location at
the time of the study and so unavailable. Mean administered 99mTc-MAA was 190 MBq. SPECT/CT
data were collected for patients whose LSF ≤ 5% to minimize error due to extrahepatic deposition
consistent with another group (19). The acquisition energy window was centered at 140 keV for
99m

Tc-MAA SPECT with 128 × 128 projection matrix over 360° for 20 seconds per azimuth and

with a low-energy high-resolution collimator. Image reconstruction was done using the ordered
subset expectation maximization (OSEM) algorithm with 3 iterations and 16 subsets, 132 × 132
matrix and 4.664 × 4.664 mm2 pixel size.
90

Y microsphere SPECT/CT imaging
In total, SPECT/CT data of 19 patients who underwent RMT with

microspheres (SIR-spheres; SIRTEX) were acquired.

90

Y-labeled resin

90

Y bremsstrahlung SPECT/CT was

performed with a medium energy general purpose collimator energy window centered on 90 keV
± 15%, 35 seconds per azimuth for 2x64 views over 360° (currently a standard protocol at our
center). Image reconstruction for 90Y SPECT was performed using Astonish from Philips Medical
Systems. Astonish is a 3D OSEM algorithm with built-in noise reduction that incorporates
attenuation and scatter corrections using the CT attenuation map and the effective source scatter
estimation method respectively, and also incorporates depth-dependent resolution recovery (61,62).
The 90Y bremsstrahlung SPECT images were reconstructed with 4 iterations and 8 subsets, 132 ×
132 matrix and 4.664 × 4.664 × 4.664 mm3 voxel size.
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Figure 14: Patient 90Y microsphere SPECT/CT images in axial (upper) and coronal (lower) views.

28

Table 5: Patient characteristics.
Patient

90

Y administered

99m

Tc-MAA SPECT/CT

activity (MBq)

available (Y/N)

1

547.60

N

2

555.00

Y

3

558.70

N

4

569.80

Y

5

758.50

Y

6

780.70

Y

7

888.00

N

8

965.70

Y

9

999.00

Y

10

1061.90

N

11

1202.50

Y

12

1195.10

N

13

1235.80

Y

14

1261.70

Y

15

1435.60

Y

16

1517.00

Y

17

2072.00

Y

3.2.2 Phantom study:
The Jasczak (Fig. 15) phantom (6 liter) which simulates a human torso was used. Eight
fillable spherical inserts of inner diameter 2, 8, 10, 12, 16, 25, 31 and 34 mm were inserted inside
the phantom to mimic variable size tumors inside the human liver (Fig. 14). For experiment 1, the
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spheres and background were filled with Yttrium-90 (III) chloride solution (PerkinElmer Inc.,
USA) of total activity 27 and 255 MBq respectively with an approximate sphere to background
activity concentration ratio of 13:1. For the second experiment,

90

Y was extracted from SIR-

Spheres using a saline solution. The solution was set for about 30 - 45 minutes for 90Y to separate
from the microspheres the microspheres to settle to the bottom. The 90Y solution was then extracted
with a needle syringe to minimize disruption of the mixture. In both experiments 90Y activity was
diluted and measured in a 60 ml vial before adding to the spheres and the activity inside each sphere
was also measured afterwards using a Capintec dose calibrator (read out scale factor = 10). The
increased activity in the spheres for experiment 2 was to be able to collect enough annihilation
events for PET/CT imaging (Table 6). The reported values in Table 6 are based on dilution
equation. Although the reading from the dose calibrator is recorded, the calibrator has ±10 read out
error for mCi measurement which might not give accurate measurement for activities in μCi. For
experiment 2, the expected values from the dilution equation might not represent exact values in
the sphere as there could be microspheres associated with 90Y invisible to the naked eye.

Figure 15: Different size hollow spheres (left) and Jasczak phantom with spherical inserts (right).
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Table 6: Phantom activity
Activity (MBq)
Sphere size in
diameter (mm)

Experiment 1

Experiment 2

S1

34

11.10

33.30

S2

31

8.88

12.65

S3

25

4.44

7.15

S4

16

1.11

4.87

S6

12

0.56

1.67

S7

10

0.28

0.85

S8

8

0.14

0.40

S9

2

~0

NA

Sphere no

Image acquisition and reconstruction
SPECT/CT imaging
Data were acquired on a dual-head Philips Precedence 16P SPECT/CT (Philips Medical
Systems Inc., USA) at the Baptist Hospital of Miami. Two separate experiments were performed
for SPEC/CT imaging. The first experiment involves imaging with two different collimators,
MEGP and HEGP. The SPECT/CT imaging setup with the MEGP collimator was identical to the
patient studies in terms of imaging window, collimator and image reconstruction. Details of the
SPECT/CT experiments are presented in Table 7.
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Table 7: SPEC/CT imaging parameters
Experiment 1

Experiment 2

Imaging 1

Imaging 2

Imaging 1

Camera brand

Philips Precedence 16

Philips Precedence 16

Philips Precedence 16

Dual-head

Yes

Yes

Yes

Field of view (FOV) 60 cm

60 cm

60 cm

Crystal type

NaI(Tl)

NaI(Tl)

NaI(Tl)

Collimator type

MEGP

HEGP

MEGP

Energy window

90 ± 15% keV

105 – 195 (150 ± 30%) 90 ± 15% keV

Reconstruction
algorithm

Astonish OSEM

Astonish OSEM

Astonish OSEM

Iterations/subsets

4/8

8/8

4/8

Post reconstruction
filter

NONE

NONE

NONE

Acquisition time

18min

18min

18min

Matrix size CT

512 × 512

512 × 512

512 × 512

Matrix size

132 × 132

132 × 132

132 × 132

Voxel size

4.664×4.664×4.664
mm3

4.664×4.664×4.664
mm3

4.664×4.664×4.664
mm3

PET/CT imaging
PET/CT data were acquired on a GE Discovery 690 TOF scanner equipped with FOV of
70 cm. PET data were acquired in the identical imaging protocol as the patient 18F-FDG PET/CT
imaging. The energy window was centered at 511 keV. Two experiments were performed; 15 or
30 min scan times. Single bed position was chosen due to the small size of the phantom where
major counts are detected along the center rings compared to a standard human size where
significant detection also occurs along the edge ring detectors. The image reconstruction algorithm
included correction for random coincidences, scatter and attenuation. Reconstructed image matrix
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was 128×128 with 5.47×5.47×5.47 mm3 voxel size. Table 8 presents details of the imaging
parameter for the PET/CT imaging.
Table 8: PET/CT imaging parameters
Experiment 1

Experiment 2

Camera brand

GE Discovery 690

GE Discovery 690

Crystal type

Germanium

Germanium

Energy window

511keV centered

511keV centered

FOV of CT

70cm

70cm

Current CT

62mA

62mA

Distance from sample

10cm

10cm

Number of projections/views

83

83

Bed position

1

1

Acquisition time

15min

30min (15min per bed)

Reconstruction algorithm

Time of Flight

Time of Flight

Matrix CT

512 × 512

512 × 512

Matrix SPECT

128 × 128

128 × 128

3.2.3 Image processing
A MATLAB® algorithm was developed to import and export images for Region and
Volumes of Interests (ROIs and VOIs) generation, semi-automatic tumor segmentation, activity
estimation, absorbed dose estimation and statistical and mathematical analysis. For the patient
studies, VOIs were drawn manually on the CT images slice by slice for liver segmentation. Binary
masks from the CT images were mapped onto the respective SPECT scans. For the phantom study,
eight circular VOIs were manually drawn on the CT slices, where knowledge of the phantom
composition allowed us to identify the spheres and made sure the volumes in VOIs were consistent
with the true measured volumes. Background VOIs consisted of all voxels within the phantom
boundary excluding voxels that belong to the sphere VOIs. A single slice through the center of the
coplanar spheres was used for generating 8 circular ROIs equal to the spheres’ inner diameter. A
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background ROI defined in the same slice consisted of all voxels within the phantom except the
sphere ROI.
3.2.4 Statistical Analysis
Quantitative parameters are presented as mean ± SD and ranges. Linear regressions were
generated between administered activities (independent variable) and cps for predicting calibration
factors. Slope, R-squared, standard error and 95% confidence interval of the regression models are
reported. Pearson correlation coefficients and were used to test for significance of correlations
between TLRs from 99mTc-MAA and 90Y SPECT and between administered activity and absorbed
doses and p values reported. Statistical analyses were deemed significant as having a p value less
than 0.05. All analyses were performed with Minitab® software package (version 17).
3.3 Results and Discussion
Five different reconstructed images from four phantom acquisitions have been used for the
analyses. Figure 16 shows the position of the phantom during acquisition and the energy resolutions
for the two collimators of experiment 1. For the HEGP collimator, the energy window is higher
and has the ability of stopping the high energy bremsstrahlung photons. As a result, the visibility
of the smaller photons has increased (Fig. 17). Although the vendor attenuation and scatter
correction is not well optimized for

90

Y imaging, based on visual inspection the inclusion of

attenuation and scatter correction in the OSEM reconstruction algorithm appears to give a better
resolution image compared to using the OSEM algorithm without the correction (Fig. 17).
The PET/CT imaging of the first experiment setup didn’t give significant counts for 15min
imaging, thus wasn’t used for analysis. The minimum count rate in PET/CT imaging of the first
experiment could be associated with the small concentration inside the spheres (0.56 MBq/ml) in
addition to the shorter imaging time. Tapp et al. (63) has performed sequential 90Y PET/CT imaging
for 5 days. The authors found that the minimum detectable concentration for phantom inserts of 10
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min PET/CT imaging was 1MBq/ml. Elschot et al. (17) used 2.4 MBq/ml inside spherical inserts
with 60 min PET/CT acquisition scan, though the imaging time used by the authors doesn’t
represent actual patient scanning (10-30 min). For the second experiment, the concentration inside
the largest spheres was approximately 1.67 MBq/ml. This change in concentration doesn’t seem to
have an impact on the SPECT/CT imaging (Fig. 18). However, the change in concentration as well
as a prolonged acquisition time gave better result of the PET/CT imaging; 3 out of the 7 spheres
are distinguishable (Fig. 19). Marti-Climent et al. (56) claimed a more realistic clinical condition
of 90Y PET/CT imaging was performed where the authors used 0.207 MBq/ml and 0.199 MBq/ml
concentrations inside the spheres and background respectively with acquisition time of 39 min.
There is great variability in 90Y phantom experimental designs in the literature, with
different sphere to background concentration ratios, different background concentrations and
different acquisition times (56). For a PET/CT study specifically these variations will impact the
count statistics as 90Y PET is concentration dependent (18).

Figure 16: SPECT/CT (left) Phantom imaging, and energy resolution of the two detectors
centered for the MEGP (middle) and HEGP (right).
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Figure 17: CT (left) and SPECT reconstructed with Astonish OSEM MEGP, OSEM only MEGP
and Astonish OSEM HEGP consecutively of experiment 1.
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Figure 18: CT (left) and SPECT (right) scans imaged with the MEGP collimator of experiment 2.

Figure 19: PECT/CT scanner and CT image (upper) and PET 15 & 30min images (lower).
3.4 Conclusion
We have collected

99m

Tc-MAA and 90Y microsphere SPECT/CT images for quantitative

comparison and dosimetry purpose. Variable

90

Y phantom experiments were performed to

investigate the optimal combination of imaging window, reconstruction algorithm, collimator type
and scan duration. A large variation was observed in 90Y experiment design among various authors.
Although these variations don’t impact 90Y bremsstrahlung SPECT/CT study due to the satisfactory
count statistics obtained, care must be taken while designing 90Y PECT/CT imaging as there is only
32 ppm of annihilation events, requiring either a larger duration of scan or a high activity
concentration compared to SPECT/CT imaging.
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Chapter 4: Spatial Resolution Recovery algorithm
4.1 Introduction
Spatial resolution is the ability of an imaging device to provide a sharp (detailed) image.
In nuclear medicine, a number factors contribute to the loss of image sharpness, such as collimator
resolution, intrinsic resolution and patient movement. In gamma cameras with absorptive
collimators, the major limiting factor of image resolution is the collimator resolution. In PET
though, the intrinsic resolution of the detectors, i.e. the size of individual detector elements, limit
the image resolution. Collimator resolution depends on the diameters of the holes and the sourceto-detector distance, which contribute to image blurring. Patient movement, such respiration and
cardiac motion, can be troublesome when imaging is performed for a longer period, but which can
be corrected by using gated-imaging techniques to minimize motion blurring. Spatial resolution in
SPECT is characterized using the profile of the reconstructed image of a line source or point source,
usually a 99mTc point source, placed in the field of view (FOV) of the camera. The profile through
the center image of the point source gives the point spread function (PSF). Spatial resolution is then
characterized by the full width at half maximum (FWHM) of the PSF. The intrinsic spatial
resolution of PET is a Gaussian function with FWHM that changes with the location of the source
from the two detectors, highest at the face of either detector.
Image restoration or spatial resolution recovery allows for correction of collimator-detector
blur which gives an improved spatial resolution. In image restoration the problem is finding an
estimate of the input image f(x,y), given the noisy and blurred image g(x,y) and PSF of the detector
written as:
𝑔(𝑥, 𝑦) = 𝑝𝑠𝑓(𝑥, 𝑦) ⊗ 𝑓(𝑥, 𝑦)
In

90

14

Y bremsstrahlung SPECT and PET imaging, correction for detector response involves

deconvolution filtering, iterative reconstruction methods that involve the PSF model of the detector
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with or without the inclusion of post reconstruction filters such as Gaussian or Wiener filter and
MC simulation to generate the collimator-detector response kernels which are associated in the
iterative reconstruction algorithm. The MC method is the best suited method of correction, but is
not widely available in the clinic to date. As a result there is a need for a more practical correction
for the collimator-detector response in 90Y bremsstrahlung SPECT and PET imaging.
4.2 Materials and Methods
It was mentioned earlier that SPECT has limited resolution due to image degrading
factors modifying the linear relationship between the projection data and the image data by
including the effects of attenuation, scatter and collimator detector response functions. Due to the
random nature of radioactive decay in SPECT and PET a Poisson model is appropriate for
emission data analysis. The Poisson model provides the probability of acquiring the projection
count distribution that was measured, P, given an estimated distribution of activity in the emission
object, f, which can be represented by the product of probabilities for individual pixels as follows:
g = 𝐏𝑓 ⟺ 𝑝(𝑠, 𝜃) = ∬ 𝑓(𝑥, 𝑦)𝑎(𝑥, 𝑦)𝑠(𝑥, 𝑦)𝑑(𝑥𝑐𝑜𝑠𝜃 + 𝑦𝑠𝑖𝑛𝑐𝜃 − 𝑠)𝑑𝑥𝑑𝑦

15

The Poisson model is well approximated by a Gaussian function provided measured counts are
reasonably high, giving a more simplified form of Eqn. 16 as,
𝐺~ 𝑃𝑜𝑖𝑠𝑠𝑜𝑛 {𝑃𝑓 + ɛ}

16

With a Poisson distribution of λ and ɛ representing the additive noises such as scattered counts. In
image restoration, the real image estimate is sought given the g as a reconstructed form of vector
G.
4.2.1 The Richardson - Lucy deconvolution method
The Richardson–Lucy (RL) technique was used for post-reconstruction image
deconvolution. The RL method was initially developed from Bayes’s theorem that relates
conditional probabilities by taking into account the statistical fluctuations in a signal. The method
is an iterative expectation maximum likelihood deconvolution algorithm (Eqn. 17) where images
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degraded by the PSF of the detector, Poisson statistics and additive noises, are corrected (64,65).
The choice of the maximum likelihood algorithm has the benefit of producing good quality images
in the presence of high noise levels by preserving positive values through accounting for
fluctuations in the signal and thus limiting noise amplification (65). This method is especially useful
in emission tomography imaging where Poisson modeling is found to be appropriate as mentioned
earlier. The Bayes’ theorem is stated as,
𝑃(𝑥|𝑦) =

𝑃(𝑦|𝑥 )𝑃(𝑥)

17

∫ 𝑃(𝑦|𝑥)𝑃(𝑥)𝑑𝑥

Where P(y|x) is the conditional probability of an event y given x, P(x) is the probability of an event
x, P(x|y) is the conditional probability of x given y (inverse probability). Relating the Bayes’
theorem to the emission tomography imaging explained in Eqns. 16 & 17 in isoplane, the
probability P(x) can be related to the radioactive distribution of object f(x,y,z) in 2D, the conditional
probability P(y|x) can be related to the PSF of the detector for a point source PSF(x,y,z,) and the
probability P(y) can be related to the degraded image g(x,y). From the inverse relationship of f(x,y,z)
and g(x,y,z), the iterative algorithm can be written as,
𝑔(𝑥,𝑦,𝑧)

𝑓𝑖 (𝑥, 𝑦, 𝑧) = {[𝑓

𝑖−1 (𝑥,𝑦,𝑧) ⨂ 𝑃𝑆𝐹(𝑥,𝑦,𝑧)

] ⊗ 𝑃𝑆𝐹(𝑥, 𝑦, 𝑧)} 𝑓𝑖−1 (𝑥, 𝑦, 𝑧)
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The algorithm requires an initial guess of the f0(x,y,z) to start the iteration where f0(x,y,z) = g(x,y,z).
In our study the PSF was fixed and the only iterative maximum likelihood estimate was the image.
4.2.2 Modeling of the point spread function of the detector
The PSF of the collimator-detector response was modeled by a 3D Gaussian kernel creating a
Poisson realization for each reconstructed pixel count. The Gaussian function for a 3D spatial is
expressed as,
3

𝑃𝑆𝐹(𝑥, 𝑦, 𝑧) = 𝜎

(2𝜋)−2

𝑠𝑥 𝜎𝑠𝑦 𝜎𝑠𝑧

1 𝑥2

𝑦2

𝑧2

𝑠𝑥

𝑠𝑦

𝑠𝑧

× exp (− 2 [𝜎2 + 𝜎2 + 𝜎2 ])
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Where σSx, σSy,σSz represent the standard deviation in the x, y, and z directions. For a spatially
invariant PSF i.e. the response to a point source of activity is the same for all points in the object,
Eqn. 19 reduces to,
𝑃𝑆𝐹(𝑥, 𝑦, 𝑧) =

1
3
(2𝜋)2 𝜎 3

𝑒 −(𝑥

2 +𝑦 2 +𝑧 2 )/2𝜎 2

20

Since scanner spatial resolution is defined in terms of FWHM of the Gaussian function of the PSF,
the σ was found by relating it with FWHM of the detector,
1
2

1 FWHM 2
) )
2σ

= exp(− 2 (

⇔ FWHM = √8 ln(2) x σ
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The iteration number for the algorithm was chosen so that convergence is reached at the point
of maximum likelihood where the resolution recovery coefficient for the 34 mm sphere was at its
maximum value. This point also corresponded to the smallest associated root mean square error
(RMSE) between two consecutive iterative image estimates (Fig. 20). Improvements in the
quantitative quality 90Y SPECT images were evaluated using contrast to noise ratio (CNR) and
contrast recovery coefficients (QH) (17) for the patient and phantom studies respectively given by
Eqns. 22 and 23. These quantitative measures were calculated by two methods: regions of interest
(ROIs) drawn through the centers of the spheres equal to the inner diameter of the spheres and
volumes of interest (VOIs) drawn on CT slices that cover the entire sphere volume with equal
diameters to the inner diameter of the spheres. This comparative measurement of quantitative
improvement in the SPECT/CT and PET/CT images based on ROIs, as opposed to a VOI method
was investigated to give an indication of the most appropriate approach for dosimetry application.
𝐶𝑁𝑅 =

𝑄𝐻 =

𝑀𝑇 −𝑀𝐵

𝐶𝑆
⁄𝐶 −1
𝐵
𝑅−1

𝑅𝑀𝑆𝐸𝑓𝑖 = [∑𝑁
𝑖
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22

√𝑀𝐵

×100
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(𝑓𝑖 −𝑓𝑖−1 )2 1/2
𝑁

]
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MT is the mean count in tumor VOIs, MB is the mean count in healthy liver VOIs, CS
is the mean count in the sphere VOIs, CB is the mean count in the background VOIs
and R is the true sphere to background ratio
Initial guess

RL algorithm

QH i > QH i-1

next iteration
Yes
i → i+1

PSF estimation

Generate
VOIsphere and
VOIBkg

No
No

RMSE i < RMSE i-1

Yes
End

Figure 20: Block diagram of the RL algorithm employed.
4.3 Results and Discussion
4.3. 1 SPET/CT study
Figure 21 shows the SPECT slice through the hot spheres of the phantom image
generated using the MEGP and HEGP collimator corrected for spatial resolution using variable
FWHM of the PSF and iterations number.
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Figure 21: Phantom image qualities for the MEGP and HEGP collimators. Column numbers
correspond to the iterations number of the algorithm and rows refer to the FWHM of the PSF.
4.3.1. 1 MEGP collimator
The QH at every iteration for 34 mm sphere measured based on ROI and VOI method is
shown in Fig. 22. The ROI method gave a highest value of QH for the sphere at the fifteenth
iteration while the maximum value was found at the sixth iteration for the VOI method. Table 9
shows summary of the results of QH for the sphere sizes using the ROI and VOI methods at the
15th and 6th iterations respectively.
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Figure 22: ROI and VOI based contrast resolution coefficient for different iteration number,
FWHM =5mm and the RMSE for the 34mm sphere.

Table 9: QH calculated using the ROI and VOI method for the sphere sizes
Sphere (diameter,
mm)

QH before (%)

34
31
25
16
12
10
Mean
Std.

29.9
28.1
22.2
7.6
8.7
-9.1
14.6
15.0

QH after_VOI
(%)
41.0
32.0
30.0
8.0
9.0
-8.0
18.7.0
18.60

QH
after_ROI
(%)
77.0
65.0
90.0
14.0
18.0
20.0
47.0
33.9

The optimal iteration number for the subsequent application of the resolution recovery
algorithm on patient 90Y microsphere SPEC/CT images was used from the VOIs analyses of the
phantom images (Fig. 23). The choice of the VOI method is due to the fact that this approach
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0.1

considers the improvement of the total reconstructed count within a volume which is required for
accurate dosimetry estimation.
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Figure 23: (A) Phantom CT scan and SPECT images for iteration numbers 0, 6 and 15 left to
right. (B) Plot of QH (right axis) and RMSE (left axis) vs. iteration number for the 34 mm sphere
(upper) and QH for the 12 mm sphere peaking at different iteration number (bottom).
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Figure 24 shows examples of improvements in the CNRs between tumor and the background for
patient 90Y microsphere bremsstrahlung SPECT/CT images. For the patients shown (Patients 5, 12
and 14), the CNRs were respectively 18.9, 14.3 and 48.8 before and 24.1, 21.4 and 51.7 after spatial
resolution recovery. For the phantom study, improvement in QH ranged between -8.3 to 41.0%.
For the smallest spheres (2, 8 and 10 mm), no improvement in QH was found. Figure 23 also shows
line profiles along the 16 and 12 mm spheres. From the profiles, it is seen that the signal in the 16
mm sphere significantly differs from the background but the signal within the 12 mm sphere and
the background are indistinguishable.
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Figure 24: Result of spatial resolution recovery showing the before and after 90Y microsphere
bremsstrahlung SPECT images of patients with the respective CT scans. (B) Line profiles through
the 16 mm (lower) and 12 mm (upper right) spheres of the phantom 90Y bremsstrahlung SPECT/CT
image. SPECT images were resized to 512x512 for display purpose hence higher pixel position for
the line profiles.
4.3.1.2 HEGP collimator
For the same FWHM (5mm) as the MEGP collimator, the following result was found for the
34mm sphere using the VOI method.
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Figure 25: (upper) QH and RMSE with 5 mm FWHM for the 34-mm sphere by HEGP collimator
SPECT/CT imaging and (lower) the before (left) and after images at the fifth (middle) and
fifteenth (right) iteration.

Figure 26 summarizes the results of QH for the MEGP and HEGP collimators at the
different sphere sizes and variable iteration number. An overall consistent increase in the QH
was observed for a FWHM of 5mm both the MEGP and HEGP collimators. Table 10 shows
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ANOVA table for the effect of the choice of collimator and FWHM for the spatial recovery
algorithm.

Figure 26: Result of QH for varying FWHM and collimator at different iteration.
4.3.2 PET/CT study
For the PET/CT study a significant change in QH was observed with a change in the
FWHM (from 5mm to 6mm) of the PSF model. FWHM of 6 mm was associated with a higher QH
of the 34 mm sphere compared to the SPECT/CT study based on ROI analysis (Fig. 27). The
iteration number for the highest QH values however, is similar for both modalities (15 iteration).
QH was higher both for the ROI and VOI method for the 30min imaging.
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Figure 27: QH (left axis) and RMSE (right axis) with 5 mm (left) and 6mm (right) FWHM for the
34 mm sphere by PET/CT TOF imaging of 15 (upper) and 30 (lower) minute imaging.
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The primary objective of this study was to develop a post-reconstruction algorithm to
quantitatively improve the

90

Y bremsstrahlung imaging using SPECT/CT and PET/CT. The

challenges for our method were image degradation due to object scatter, septal penetration and
backscatter. Despite the inherent shortcomings, we achieved a meaningful improvement in CNR
and QH which were measured in clinical and phantom

90

Y bremsstrahlung SPECT/CT images

respectively. The small spheres (2, 8 and 10 mm) showed indifferent results before and after
resolution recovery. The challenge to draw the ROIs introduces extra errors in addition to the fact
that the volumes might be highly influenced by noise. The smallest volume that gave an acceptable
result was the 16 mm sphere with substantial signal difference from the background. Our result of
the highest QH for the 34 mm sphere was 41% using a matching VOI. Using similar methods used
by other authors to evaluate QH (17,66), that is using an ROI in the slice through the center of the
spheres, we found a higher value of QH ~ 80% for the 34 mm sphere. It is worth noting that there
are other methods of measuring the background ROI as well. Martí‐Climent el al. (56) measured
the background from ROIs drawn similar to the sphere diameter of interest throughout the image.
The authors studied the QH in 90Y PET/CT study of a Jasczak phantom with six spheres. The sphere
VOIs were generated in a similar manner to our method. The authors reported QH = 60% in a 28
mm sphere for 90Y PET/CT images reconstructed with OSEM+PSF with TOF described as the
optimal method. In our study, the

90

Y images reconstructed with OSEM algorithm with TOF

PET/CT corrected with post-reconstruction PSF, the result of a closest sphere volume (25 mm)
gave QH = 75%. Although the method used by the authors is feasible, when considering a range of
hot concentrations in a warm background that is representative of a microsphere distribution, taking
a background measurement as small as the sphere size in different areas that could have no activity
might not quite represent the scenario in RMT.
A recent work to correct 90Y bremsstrahlung SPECT/CT images was done by Simen et al.
(19). The authors used a technique called background compensation. The technique entails two
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separate imaging of a subject for energy window based scatter correction, but the method highly
relies on the selection of energy windows. Energy based scatter correction is different in different
makes and models of cameras with different collimator types, thus replication of the method in the
clinical environment is impractical. Using this method the authors reported resolution recovery
coefficient of 90% for a 37 mm sphere in a 10 mm VOI, much less than the actual sphere VOI.
Our spatial resolution algorithm corrects images for the effect of PSF. The statistical basis
of the algorithm makes it suitable for application on nuclear medicine images. In addition, the
restoration algorithm is image dependent instead of dependent on the camera make and model
through the inclusion of the RMSE criteria between two consecutive iterative images. The
restoration algorithm which corrects for the collimator response will also implicitly correct for
scatter. This is due to the fact that scatter photons degrade the PSF giving it a long tail especially,
in PET camera. Thus the restoration algorithm is capable of improving both the accuracy and
precision of the 90Y bremsstrahlung SPECT and PET images.
4.4 Conclusion
The proposed spatial resolution algorithm for quantitative image improvement of

90

Y

bremsstrahlung SPECT/CT and PET/CT gave meaningful results in phantom and patient studies.
The method utilizes current clinical 90Y imaging protocols thus can be readily applied in the clinical
environment. For the PECT/CT study, however the method can be further tested for different
acquisition times and activity concentrations as well as on actual patient 90Y PET/CT images.
Chapter 5: Calibration factor and Activity estimation
5.1 Introduction
In nuclear medicine internal radionuclide dosimetry absolute quantification is a
requirement (32). The objective is to provide reconstructed images with each voxel representing
the absolute activity concentration in the corresponding region in the patient. Absolute activity
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concentration has many uses in nuclear medicine, such as patient-specific dosimetry in radiotherapy
treatment planning and monitoring, tumor classification, and detection of vessel diseases in cardiac
imaging. This is achieved by conversion of voxel counts per second (cps) values to activity
concentration (Bq) which requires determining the camera calibration factor (sensitivity). The most
reliable method to determine the calibration factor (cps/Bq) of a detector is to perform an
experiment such as a point source with a known activity concentration, A (Bq/ml), of the
radionuclide of interest in a setting with minimal image degrading effects (15,32). The calibration
factor is then determined by dividing the total reconstructed counts, C (counts/per voxel/sec),
within the volume of interest by the known radionuclide activity. In PET though, the fraction of the
decay, i.e. the branching fraction (B.F.), that occur via positron emission for the radionuclide of
interest should be included in the calculation of the calibration factor (11). This is due to the fact
that most radionuclides used in PET imaging don’t decay by 100% positron emission, thus the CF
in PET is given as:
𝐶𝐹 =

𝑐𝑜𝑢𝑛𝑡𝑠
)
𝑣𝑜𝑥𝑒𝑙×𝑠𝑒𝑐
𝐵𝑞
𝐴 ( ) × 𝐵.𝐹.
𝑚𝑙

𝐶(
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Applying a calibration factor calculated using a point source to a population of humans
who exhibit variability in terms of anatomy and biokinetics introduces error (67). The error is
exacerbated in bremsstrahlung imaging due to attenuation, scatter and collimator-detector effects.
In addition, the CF of 90Y imaging in PET depends on the activity concentration inside a volume
rather than total activity (18). As a result, mostly, phantom studies more representative of humans
are used for estimating a calibration factor in 90Y imaging. Even using a phantom (such as the IEC
body phantom) for the calibration study has shown a substantial bias as it doesn’t accurately
represent clinical imaging conditions in terms of bremsstrahlung photon attenuation and scatter
(19). A direct solution that represents the clinical scenario, i.e. using clinical studies or animal
studies, has been suggested for calculation of a calibration factor for absolute quantification (67).
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Animal studies, however, don’t quite represent humans in terms of size, the biokinetics and
geometric size of the organ uptake that affect the attenuation and scattering of photons. Human
studies on the other hand require obtaining sufficient numbers of patients under a similar
acquisition protocol. Thus solving for calibration factor that address the unique condition in 90Y
imaging under a clinically relevant condition to be able to provide the clinical user with absolute
quantitative values is an active research area. In the present chapter, we developed and evaluated
an approach to quantitate 90Y imaging. The goal is to assure clinical practicability and to establish
a baseline for image based calibration factor generation.

Figure 28: (left) Rod phantom and (right) IEC body phantom used in calibration factor study (68).
5.2 Materials and Methods
5.2.1 Calibration Factor
In order to obtain absolute quantification values from reconstructed SPECT and PET
images, calibration of the imaging system is necessary. We propose two methods to derive absolute
activity quantification in MBq from counts of the reconstructed images. For the SPECT/CT study
calculation the calibration factor was done from the spatially recovered

90

Y microsphere

SPECT/CT of the 17 patients. The first approach (method 1) uses the entire total reconstructed
counts within the field of view (FOV) of the SPECT detector (Fig. 29). The second approach
(method 2) used counts from the liver segments only. In this method, the liver was first segmented
as described in the image processing section and total counts within the liver VOIs were taken. This
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method avoids counts due to image artifacts. Calibration curves were generated using linear
regression analysis to derive the relationship between patient administered dose and reconstructed
counts. The CFs were calculated from the slopes of the calibration curves.
For the phantom study, the total reconstructed counts within the phantom boundary were
considered. The total activity for the phantom was the sum of the activities inside the spheres and
the background. The CF from the phantom study was evaluated to be within the 95% confidence
interval (CI) of the calibration curves from the

90

Y microsphere SPEC/TCT patient studies to

validate its application on the phantom images. For the PET/CT phantom study, the activity inside
the phantom was adjusted for a B.F of 0.003% as explained earlier.
Since we sought to investigate the distribution between pre and post-treatment images, we also
calculated calibration factor for the 99mTc-MAA imaging using a line source both in air and water
as shown in Fig. 30.
The calibration factor (CF) for all the phantom studies was defined as in Eqn. 26,
𝐶𝐹 =

∑𝑗∈ 𝑉𝑂𝐼 𝑓𝑗
𝐴𝑐𝑜𝑟𝑟
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where fj is the reconstructed counts from the corrected images in the jth voxel that belong to the
defined VOIs, and the Acorr is the total true administered activity corrected for decay from A0
measured at the time of activity calibration t0 (assumed to be 0) to the start time of image acquisition
ti using a decay constant (λ) given as,
𝐴𝑐𝑜𝑟𝑟 = 𝐴0 𝑒 −𝜆(𝑡𝑖−𝑡0)
𝜆=

𝑙𝑛2
,
𝑇1/2
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27

where T1/2 is the half-life of 90Y, which is 64.0 hr. (43). Since the half-life of 90Y is much longer
than the image acquisition time, the radioactive decay that occurs during the acquisition is not
corrected. The decay corrected calibration factor in the VOI is then,
𝐶𝐹 = 𝑒 −𝜆(𝑡𝑖) ×

∑𝑗∈ 𝑉𝑂𝐼 𝑓𝑗
𝐴0

28

The precision of the calibration factor could of course be impacted by the dose calibrator
measurement (±2 % as specified by the manufacturer), experimental error such as activity and
volume measurement and statistical variations of the measured counts. Patient administered
activities were also corrected for decay with an average time of ti = 2 hr. which is the time between
when the injected activity is calibrated and patient imaging. There is also a discrepancy here due to
the logistics of the clinical setup where the time of activity calibration and actual administration to
the patient might have been recorded as similar events.

Figure 29: Anatomical representation (transverse, coronal and sagittal view) of method 1 (upper)
and method 2 (lower) of calculating the CFs for the patient study.
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Figure 30: SPECT/CT imaging window of 99mTc (left), and line source filled with 99mTc solution
in air (middle) and water media (right).
5.2.2 Activity estimation
The activity of 90Y at a reconstructed pixel and in a defined volume was given by Eqn. 29
and 30 respectively. For the patient studies, total liver activity estimation was compared to the true
administered dose. For the phantom study, activities inside the eight spherical inserts were
compared to the activities measured using the dose calibrator. The relative percent error between
true and estimated activity was determined by Eqn. 31.
𝐴𝑖,𝑗,𝑘 =

𝐴𝑉 =

𝑓𝑖,𝑗,𝑘
𝐶𝐹

,

∑𝑖,𝑗,𝑘 ∈𝑉𝑂𝐼 𝑓𝑖,𝑗,𝑘
𝐶𝐹

%𝐸𝑟𝑟𝑜𝑟 =

𝐴𝑐𝑜𝑟𝑟 −𝐴𝑉
×100
𝐴𝑐𝑜𝑟𝑟
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5.3 Results and Discussion
5.3.1 Calibration factor
Results of the regression analyses (Fig. 31) of the relationships between cps and
administered activity gave the following results for the patient study, the slopes being the CFs
(cps/MBq); method 1, CF1 = 20929 cps/MBq with 95% CI 16,281 ≤ β ≤ 25,576 cps/MBq (R2 =
0.86 and standard error (SE) = 2181) and method 2, CF2 = 8389 cps/MBq with 95% CI of 7050.7
≤ β ≤ 9729.3 (R2 = 0.92 and SE = 628). The CF from the phantom SPECT/CT study is 9049
cps/MBq, which doesn’t fall within 95% CI of CF1 but does fall within the 95% CI of CF2.
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The HEGP collimator imaging gave a CF = 14,990 and 15,086 cps/MBq for FWHM of 5 and 6 mm
respectively. For the PET/CT phantom study, the measured CF of the camera was 6844 cps/MBq.

Figure 31:Linear regression plots of the calibration curves with the 95% CI range (green dashed
lines) for method 1 (left) and method 2 (right).
5.3.2 Activity estimation
5.3.2.1 Patient Study
The total activity inside the liver was estimated for each patient using the CFs derived from
the two methods. For CF1, total liver activity estimation resulted in mean percent error of 59 ± 5%.
Applying CF2 gave the smallest error (-4 ± 12%), thus it was used for subsequent analysis. Table 9
shows results of total activity estimation within the liver VOIs using CF2. For 12 out of 17 patients,
the estimated total liver activity percent errors were within ±10% giving overall satisfactory results.
As our study is retrospective based on anonymized data, we couldn’t provide possible clinical
reasons for the larger deviations of the estimated activities.
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Table 10: Administered activities and total estimated activities inside liver VOI.
Administered Activity

Estimated Activity

Patient No

(MBq)

(MBq)

Error (%)

Pat_1

548

598

-9

Pat_2

555

480

14

Pat_3

559

523

6

Pat_4

570

652

-14

Pat_5

759

967

-27

Pat_6

781

788

-1

Pat_7

888

800

10

Pat_8

966

1251

-30

Pat_9

999

1009

-1

Pat_10

1062

1003

6

Pat_11

1203

1202

0

Pat_12

1195

1323

-11

Pat_13

1236

1221

1

Pat_14

1262

1288

-2

Pat_15

1436

1350

6

Pat_16

1517

1572

-4

Pat_17

2072

2188

-6

Mean

1036

1071

-4

Std.

410

432

12
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5.3.2.2 Phantom Study
Table 11 shows results of activity estimates inside the spheres and background for the
phantom study with total mean percent error of -23 ± 41% for the MEGP collimator. Table 12
shows ANOVA study that summarizes the effect of the choice of collimator and FWHM for the
spatial resolution recovery on accurate activity estimation. The result shows that for the specific
acidity used in our study, collimator choice is insignificant (p = 0.17) whereas the FWHM plays is
an important factor for accurate activity estimation.
Table 11: Phantom true and estimated activities.

% Error

Estimated Activity (MBq)

Diameter
(mm)

True
Activity
(MBq)

MEGP

HEGP@5

HEGP@6

MEGP

HEGP@5

HEGP@6

34

11.10

11.55

9.23

9.55

-4.05

16.88

13.95

31

8.88

9.16

8.40

8.67

-3.15

5.35

2.31

25

4.44

4.50

4.31

4.48

-1.35

2.87

-0.82

16

1.11

1.17

1.21

1.23

-5.41

-8.84

-10.39

12

0.56

0.62

0.61

0.63

-10.71

-10.79

-13.80

10

0.28

0.36

0.48

0.47

-28.57

-71.35

-67.86

8

0.14

0.31

0.00

0.00

-121.47

100.00

100.00

6x103 ml

255.30

282.93

183.69

183.32

-10.82

28.05

28.19

Mean

35.23

38.83

25.99

26.04

-23.19

7.77

6.45

Std.

89.02

98.73

59.70

59.55

40.62

47.68

47.16
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Table 12: ANOVA for the choice of collimator and FWHM
Analysis of Variance
Source
DF Adj SS
Collimator
2 1.0337
FWHM
1 7.0064
Error
2 0.2124
Total
5 8.2525

Adj MS
0.5169
7.0064
0.1062

F-Value
4.87
65.98

P-Value
0.170
0.015

With the clinical available reconstruction method and application of spatial resolution
recovery algorithm, total liver activity estimation gave percent error of -4 ± 12 using the CF found
from counts within the liver VOIs with the MEGP collimator. Siman et al. (19) generated a global
CF derived from patient studies where entire counts within the FOV were considered. The global
CF was applied to an IEC phantom with a 37 mm sphere insert and the authors reported an error of
-25% with respect to the true activity. For our phantom study, we used CF estimated from the total
reconstructed counts, which fall within 95% CI of the patient calibration curve, and error as low
1% in the 25 mm sphere was achieved with total mean percent error -23 ± 41%. Sphere volumes ≤
12 mm resulted in the highest error.
The HEGP collimator study gave total mean percent error of 7.77 ± 48% and 6.45 ± 47%
with FWHM of 5 and 6mm respectively. The overall calculated error is much less for HEGP
compared to the MEGP collimator study estimated activity values. The activity inside the smaller
volumes (8 & 10 mm) is overestimated in the HEGP collimator although the volumes showed an
improved resolution compared to the MEGP collimator. The fact that attenuation and scatter
correction of the vendor is not optimized for the HEGP collimator at the image acquisition window
(150 ± 30%) might have contributed the higher discrepancy of activity estimation. For specified
SPECT acquisition window, the CT transmission imaging should have to be centered at 140 keV
to correct for the attenuation. Due to technical difficulty this wasn’t achieved in our HEGP
collimator study.
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The PET/CT study measurement in areas of high activity, such as the 34 and 25 mm
spheres, gave errors of -1.1% and 6.1% respectively for the 30 min imaging. For estimates in value
regions of low activity, such as the 12 mm sphere, error in the order of 57% was observed. The 90Y
PET imaging gave a more accurate estimation of the true activity in areas of high activity compared
to 90Y bremsstrahlung SPECT/CT imaging. However, the SPECT imaging gave a much lesser error
in areas of low activity compared to similar measurement in PET.
5.4 Conclusion
Approaches for calculating image based CF were evaluated. For the 90Y microsphere
patient study, CF generated counts from the liver VOIs gave a much more accurate result
compared to a CF generated from counts within the entire FOV of the SPECT/CT camera. In the
phantom SPECT/CT study, the HEGP collimator gave an overall lower error of activity
estimation however, it resulted in higher discrepancy in the smaller sphere volumes. It is observed
that SPECT images give better results in low activity areas than PET images. But the two images
give comparable results in high activity areas.
Chapter 6: Comparison of tumor to healthy liver ratio on 99mTc-MAA vs. 90Y microsphere
SPECT/CT
6.1

Introduction
The protocol of RMT with 90Y involves a prior liver perfusion scan with 99mTc-MAA using

planar and SPECT/CT imaging. This prior assessment serves as a surrogate of microsphere
distribution to assess lung shunting, endovascular mapping, extrahepatic deposition, to predict
absorbed dose in target volumes and to select the catheter position for tumoral targeting (69).
Various authors have investigated the predicted dosimetry with the actual

90

Y microsphere

distribution in SPECT/CT or PET/CT imaging (10,69-71). Accurate tumor and healthy liver
predictive dosimetry is essential for patient safety, and evaluation of dose response (10). But a
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quantitative uptake analysis of tumor and nontumoral liver requires a precise calculation of the
vascularized volume. Generally, this calculation is done on CT which is relatively easy. But in
cases where there is anatomical variation, such as when multiple distinct arterial branches
vascularize the liver, CT based functional liver volume calculation is problematic (30). In this case,
depending on the radionuclide of interest, SPECT or PET is used for calculating the functional liver
volume vascularized by each separate arterial branch. In most studies though, that compared 99mTcMAA and 90Y microsphere uptake distribution, tumor areas were delineated on the CT scans. In
addition, the two images were evaluated separately, i.e. separate tumor segmentation was done on
the CT scans of

99m

Tc-MAA and

90

Y microspheres (70-72). The method of CT based tumor

delineation is cumbersome for large data sets with multiple tumors per patient requiring a repetitive
task on the separate

99m

Tc-MAA and

90

Y-microsphere images. In addition CT based tumor

delineation will take into account cold areas within the tumor, such as necrosis, which will
overestimate tumor volume but underestimate tumor dose (69). Thus, a more reliable method of
tumor delineation for dosimetry purpose and a less cumbersome method that avoids a repetitive
task is essential in order to compare the 99mTc-MAA and 90Y microsphere distributions.
6.2 Materials and Methods
6.2.1 Co-registration of 99mTc-MAA vs. 90Y SPECT
To compare the correlation between uptake distribution on

99m

Tc-MAA and

90

Y

microsphere SPECT/CT images, the two images were co-registered as the two SPECT/CT images
have different number slices and voxel sizes (Fig. 32). Image registration involves estimating a
mapping between a pair of images. One image is assumed to remain stationary (the reference
image), whereas the other (the source image) is spatially transformed to match the stationary image.
We have tried two approaches; taking the CT images as a reference (“fixed image”) and
the SPECT images as a source (“moving image”). In the second method, 90Y microsphere SPECT
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was taken as the reference image and the

99m

Tc-MAA SPECT and 90Y CT images provided the

source images. The latter method was tested to preserve the counts in the 90Y microsphere SPECT
images from being inter and/or extrapolated by the registration method.

Figure 32: Variation in the number of slices and voxel sized between the CT and SPECT slices
between the pre and post-treatment images.
Two image registration tools were used, FMRIB's Software Library (FSL) and Statistical
Parametric Mapping (SPM), both well-established tools extensively used in neural imaging for
registering anatomical and functional images (73). We found visually best results using SPM thus
the following explanation will focus on the details of SPM.
Statistical Parametric Mapping Registration
Statistical parametric mapping (SPM) is used to identify regionally specific effects in
imaging data and is a suitable approach for characterizing functional anatomy and tumor related
changes (73). SPM is a voxel-based approach that employs topological inference. The method
entails the construction of continuous statistical processes to test hypotheses about regionally
specific effects (73). The statistical parametric maps are image values that are distributed according
to a probability density function under the null hypothesis, usually the Student’s t or F-distribution.
Statistical analysis of image data corresponds to inverting generative models of the data to partition
observed responses into components of interest, confounds and error. Inferences are then pursued
using statistics that compare interesting effects and the error, i.e. each and every voxel is analyzed
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using statistical test (73). The resulting statistical parameters are then assembled into an image
which are continuous statistical processes of random fields. Random fields model the univariate
probabilistic characteristics of an image and non-stationary spatial covariance structure.
Various tools in the SPM software has been tested. The most relevant to our work were: Rigid
body registration and Non-linear registration. Rigid body registration is one of the simplest forms
of image registration commonly used for registering within modality or different modality images
of a single subject. Images are aligned by finding the rotations and translations that optimize some
mutual function of the images. However, rigid body registration is limited to optimizing differences
of the images due to subject movement.
Our research question not only addressed subject movement but also changes in the shape of
functional volumes from image distortion due to image degrading factors explained in the
SPECT/CT imaging section above. These distortions can result in a significant signal accumulation
over numerous scans. Non-linear registration addresses differences purely due to image artefacts,
as well as interaction due to image distortion, and movement of the subject are considered in nonlinear image registration. The spatial normalization function of SPM12 uses this principle, and
hence is applied in this work. To choose the most appropriate approach, that is, using either the CT
or the 90Y SPECT as the reference image (Fig. 33), we calculated the mutual information between
the co-registered

90

Y microsphere and

99m

Tc-MAA SPECT images from the two methods. The

mutual information between the two images is defined as:
𝐼(𝐴, 𝐵) = 𝐻(𝐴) + 𝐻(𝐵) − 𝐻(𝐴, 𝐵)
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𝐻(𝐴) = − ∑𝑎 𝑝𝐴 (𝑎)𝑙𝑜𝑔𝑝𝐴 (𝑎)
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𝐻(𝐵) = − ∑𝑏 𝑝𝐵 (𝑏)𝑙𝑜𝑔𝑝𝐵 (𝑏)

34

𝐻(𝐴, 𝐵) = − ∑𝑎,𝑏 𝑝𝐴,𝐵 (𝑎, 𝑏)𝑙𝑜𝑔𝑝𝐴,𝐵 (𝑎, 𝑏)
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H (A) and H (B) are the entropy of images A and B respectively, and H (A, B) is their joint entropy,
pA and pB are probability distributions (histogram) of image A (99mTc-MAA) and B (90Y
microsphere) and pA,B is the joint probability distribution of A & B. The method which gave the
highest I (A, B) was used for registering the images. Details of the calculation of mutual information
is explained by Maes et al. (74). Mean CPU time to register two images was about 15 minutes on
a standard PC.

B)

A)

C)

Figure 33: Registration via changing the fixed image: (A) CT of pre-treatment, (B) CT of posttreatment and (C) SPECT of post-treatment.
6.2.2 Tumor segmentation
Tumor segmentation was important to compare the uptake patterns in the pre and posttreatment images. Quantitative uptake analysis on 99mTc-MAA SPECT/CT for tumor delineation is
usually done using an isocontour method with a dedicated software (9). Tumor segmentation based
on global thresholding approach is the simplest and most popular technique in image segmentation
(75). However, this method is not feasible for our project. Applying a global thresholding on two
functional images with huge differences in the administered activity imposes a bias favoring either
of the two images depending on the value of the threshold, as shown in Fig. 34. Thus, we sought a
method that is specific to the image of interest, and also considers the noise and abrupt changes in
image intensity values. The latter criteria are a requirement of our study due to the distribution of
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99

Tc-MAA and 90Y microspheres which are expected to be localized more in tumor tissue than in

the healthy liver (31). Thus, the challenge here is to accurately extract tumor contours.
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Figure 34: Scatter plot of 90Y microsphere SPEC images for patient 10 (left) and 13 (right) with
administered activity of 1061.90 and 1235.8 MBq respectively.

To overcome these challenges tumor segmentation based on the uptake of

99m

Tc-MAA and 90Y

microspheres was performed using an active contour segmentation method to delineate areas of
high activity (tumor) from the surrounding low activity (healthy) liver.
6.2.2.1 Active contour based tumor segmentation
Active contour detects specified features by evolving a curve in a given image where the
evolution stops when the curve meets a boundary (76). The magnitude of the gradient of the image
is used to stop the curve. But the gradient based methods suffer a limitation from the fact that only
edges defined by the gradient of the local information are detected. An alternative is to use a global
segmentation of the image to stop the curve. Chan-Vese (CV) et al. (77) has developed an active
contour method that addresses this limitation by introducing an energy based segmentation via a
multi-phase level set approach (Eqn. 36). The CV method is an iterative technique that allows for
automatic detection of interior contours, and segments images with complex topologies into
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multiple segments (77). This technique is particularly important in tumors with a necrotic core
where there is a minimal uptake within the core. The iteration number for the algorithm was chosen
based on the convergence criteria where the segmented tumor volume no longer changes in size
(Fig. 35).
𝐶𝑉 = ∫(𝐼𝑜 (𝑥, 𝑦) − 𝑐1 )2 𝐻(𝜙)𝑑𝑥𝑑𝑦 + ∫(𝐼𝑜 (𝑥, 𝑦) − 𝑐2 )2 𝑑𝑥𝑑𝑦

36

Figure 35: The iterative CV active contour segmentation method for different iteration number.
Io (x, y) is intensity of the input image, c1 and c2 are mean intensities within the inside and outside
contour curve respectively, and H() and ϕ are the Heaviside and level set functions respectively.
6.2.3 Tumor to healthy liver ratio
In order to avoid the bias of very high and very low counts we used a mean based ratio to
calculate the TLRs. As counts are proportional to activity concentration, the TLR for a given tumor
was defined as,
𝑇𝐿𝑅 =

𝑡̅ (𝑖,𝑗,𝑘)
̅̅̅̅̅̅(𝑖,𝑗,𝑘)
𝑏𝑘𝑔

t̄ and b͞kg are the mean counts per pixel of the tumor and healthy liver respectively.
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6.3 Results and Discussion
6.3.1 Co-registration of 99mTc-MAA and 90Y SPECT/CT
Figure 36 shows results of the three co-registration approaches where the CT scan of the
post-treatment as a reference image gave the best alignment between the images. Using the

90

Y

microsphere SPECT image as a reference also gave a good result, visually comparable to the
aforementioned result. Figure 37 shows plots of the probability distribution of the pre and posttreatment images and their joint distribution after co-registration which were used for subsequent
calculation of the mutual information. The mutual information is higher or equal in most patients
where the CT scan was the reference image [Fig. 38(A)]. In other patients, for example patient 11,
the

99m

Tc-MAA and

90

Y microsphere SPECT images didn’t co-register correctly with the CT

image. From the SPECT scans of this patient, we observed that the patient had a hepatic tumor with
a necrotic core with minimal uptake inside the liver, which reduced the mutual information required
for co-registering the SPECT and CT scans [Fig. 38(B)]. Patient 6 showed the smallest of all mutual
information between

99m

Tc-MAA and

90

Y microsphere SPECT scans and like the previously

mentioned patient, the SPECT scan didn’t co-register well with the CT scan. We observed that the
99m

Tc-MAA and 90Y microsphere SPECT scans of this patient have exclusively localized activity

in the left lobe (Fig. 39). For these patients image analyses on the 99mTc-MAA and 90Y microsphere
SPECT/CT were performed separately.
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A

B

C

Figure 36: Patient 9 (left) and 13 (right) co-registered CT and SPECT images of 99mTc-MAA (blue)
and 90Y (red) for reference images of CT of post-treatment (row A), CT of diagnostic (row B) and
90
Y microsphere SPECT (row C). The arrows in (B) show the misalignment between the CT and
SPECT images showing activity distributions outside of the liver boundary in the coronal and
sagittal views.
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Figure 37: Plot of the probability distribution of the pre and post-treatment (upper) images and
their joint distribution after co-registration.
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Figure 38: (A) Mutual information between co-registered 90Y microsphere and 99mTc-MAA SPECT
images. (B) Patient 11 CT (left), 99mTc-MAA (middle) and 90Y microsphere (right) SPECT scans
showing a minimal uptake within the liver.

Figure 39: Patient 6 CT (left), 99mTc-MAA (middle) and 90Y microsphere (right) SPECT that
showed the smallest mutual information between the co-registered pre and post-treatment images.
6.3.2 Tumor segmentation
The 99mTc-MAA and 90Y microsphere SPECT/CT images showed variable iteration
number of convergence (Fig. 40). For consistency of applying similar iteration number to both
images, we applied 400 iterations. Manual segmentation of whole liver for all patients ranged
between 1120 – 3389 (mean: 2345 ± 740) ml. For 99mTc-MAA, tumor volumes ranged between
160 – 1010 (695 ± 275) ml. 90Y-microshpere uptake gave tumor volumes in the range of 207 –
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1868 (786 ± 462) ml. Figure 41 shows the Box-Whisker plot of the three volumes. 90Ymicrosphere SPECT/CT images gave an overall higher tumor volume for most patients compared
to the 99mTc-MAA SPECT/CT images. A paired t-test of the two volumes gave insignificant
difference (t-value = -0.82, p-value = 0.429), as shown in Table 13.
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Figure 40: Plot of the segmented tumor volumes at each iteration for determining optimal
iteration number (n) at the convergence (ε) calculated between consecutive volumes (vn and vn-1)

Figure 41: Segmented tumor in axial and coronal view.
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Figure 42: Box plot of whole liver and tumor segmented volumes.

Table 13: Minitab result of paired T-test between pre and post-treatment tumor volumes.
Paired T for 99mTc-MAA - Y-90 microsphere
N Mean StDev SE Mean
99mTc-MAA
12
695
275
79
Y-90 microsphere 12
786
462
133
Difference
12
-91
383
110
T-Test of mean difference = 0 (vs ≠ 0): T-Value = -0.82
P-Value = 0.429

6.3.3 TLR calculation and comparison
Table 14 presents results of the TLRs for each patient. The total mean TLR was 9.2 ± 9.4
and 5.0 ± 2.2 on 99mTc-MAA and 90Y microsphere SPECT/CT respectively. Figure 43 shows the
scatterplot of mean TLRs from the two images displaying a significant correlation (r = 0.9, p<0.05).
From the plot, patient 2 is an outlier (Grubbs’ outlier test, p-value = 0.00) and taking this patient
out of the analysis gave a reduced correlation (r = 0.6, p < 0.05).
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Table 14: Mean TLR on 99mTc-MAA and 90Y SPECT images.
Tumor to liver ratio (TLR)
Patient no.

99m

Tc-MAA

90

Y

Pat_2

36.3

11.5

Pat_4

7.0

3.5

Pat_5

4.8

4.8

Pat_6

11.7

5.0

Pat_8

5.6

4.3

Pat_9

2.7

2.6

Pat_11

3.8

4.2

Pat_13

10.2

5.3

Pat_14

4.4

4.8

Pat_15

1.8

3.8

Pat_16

7.5

4.6

Pat_17

14.9

5.0

Mean

9.2

5.0

Std.

9.4

2.2
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Figure 43: Scatterplot illustrating correlation between mean TLRs in 90Y and 99mTc-MAA
SPECT.
Comparing the

99m

Tc-MAA distribution of patient 2 with other similar patient scans (Fig. 44)

revealed that the localized distribution might have contributed to the higher TRL ratio as there is
minimal or no significant uptake in the healthy liver. But this scenario needs further investigation,
which can be achieved by dividing the patient cohort into two, those who had left or right lobe
treatment. This kind of comparison will help decide if the TLR ratio is affected by a localized vs.
a decentralized distribution for the specific lobe treatment.
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Figure 44: Comparison of 99mTc-MAA SPECT/CT uptake distribution between patient 2 (left)
and patient 8 (right).
The predictive accuracy of 99mTc-MAA regarding the actual 90Y microspheres dose distribution
and its impact on patient outcomes is a source of controversy. Ilhan et al. (10) have studied the
relationship between

99m

Tc-MAA and

90

Y microspheres uptake in a retrospective study which

involved 502 patients with various liver cancer types (10). This study found a weak correlation
between the mean tumor to background (healthy liver) ratios of

99m

Tc-MAA SPECT/CT and 90Y

microsphere SPECT/CT images. We believe a comparison of the pre and post-treatment images of
90

Y microspheres and 99mTc-MAA may help evaluate the discordance between MAA distributions

versus actual microsphere distribution. There are known factors that could contribute to
discrepancies. First and foremost is the variable size and shape of the macro-aggregated albumin
particles and clusters. Additional factors may include the embolizing effect in 90Y, and differences
in positioning of the catheter tip between the 99mTc-MAA and 90Y microsphere procedures.
Prior to quantitative comparison, the pre and post-treatment SPECT/CT images were coregistered. The accuracy of the comparison strongly depends on the proper matching of the two
images in all three dimensions. From our results, we found that this alignment depends on the
overall content of liver activity within the SPECT scans which could be attributed to the fact that
SPM is based on identifying regionally specific effects in the imaging data (2). As a result, the
registration didn’t provide very accurate alignment between the CT and SPECT images in cases
such as a necrotic tumor covering a larger portion of the liver. In these cases, manual matching of
the 99mTc-MAA SPECT/CT and 90Y microsphere SPECT/CT images was necessary.
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Tumor segmentation gave higher mean volumes in the post-treatment images compared to
the respective pre-treatment images. Although the difference between the volumes is insignificant
(p-value = 0.429), since the tumor segmentation is based on higher activity concentrations, it is
possible that the tumor ROIs didn’t necessarily coincide with the tumorous tissues in the

90

Y

microsphere SPECT/CT images. However, it is expected in radioembolization that higher
microsphere accumulation is to be in tumorous regions rather than the healthy liver parenchyma
(17).
To minimize outlier effects, we used the ratio of the mean activities between the tumorous
and healthy liver to calculate the TLRs. The mean TLRs between 99mTc-MAA and 90Y microsphere
SPECT/CT images showed a strong correlation with one patient as an outlier where removing this
patient gave a much lower correlation. Although statistically correct, for the patient to be
considered as an outlier in terms of invalid treatment the statement falls short. Ilhan et al. (10)
states that the TLRs from

99m

Tc-MAA SPECT/CT is higher in all patients compared to the

respective 90Y microsphere SPECT/CT scans, which the authors believe to be due to the poor image
quality of 90Y bremsstrahlung SPECT/CT. In our study, we found that after 90Y bremsstrahlung
SPECT/CT image improvement the TRLs were higher in 99mTc-MAA SPECT/CT for most of the
patients, and others showed a higher 90Y microspheres uptake over the 99mTc-MAA. The standard
deviation of the TLRs on

90

Y microspheres SPECT/CT images is lower than

SPECT/CT which could be associated with the embolizing effect of

99m

Tc-MAA

90

Y microsphere particles

(9,10).
6.4 Conclusion
The objective of this study was the comparison of the uptake distributions between pretreatment

99m

Tc-MAA and post-treatment

90

Y microsphere SPECT/CT images. The study

investigated various methods and their feasibility for co-registration of the

75

99m

Tc-MAA and 90Y

microsphere SPECT/CT images. In addition, tumor segmentation suitable for pre and post RMT
images was sought. In the end, we identified a substantial correlation in mean TLRs between 99mTcMAA and 90Y microspheres SPECT/CT uptake distribution.

Chapter 7: Dosimetry algorithm
7.1 Introduction
Absorbed dose (dosimetry) is the mean energy imparted to target tissue per unit mass (Eqn.
38) (78). Techniques for post-treatment

90

Y microsphere imaging dosimetry have grown

significantly in recent years. The compartmental (partition) model by the Medical Internal
Radiation Dose (MIRD) is the first method to characterize dose independently to target tumor and
healthy part of the liver (79). The primary MIRD formula (non-compartmental model) used to
determine absorbed dose from an imaging scan is given by Eqn. 38 where the anatomical volumes
are determined based on standard human size (Fig. 45). The compartmental model however
partitions the liver into the normal liver and tumor (80) given by Eqn. 39-41.
𝐷(𝐺𝑦) =

𝐸𝑛𝑒𝑟𝑔𝑦 𝐴𝑏𝑠𝑜𝑟𝑏𝑒𝑑 𝑓𝑟𝑜𝑚 𝐼𝑜𝑛𝑖𝑧𝑖𝑛𝑔 𝐸𝑛𝑒𝑟𝑔𝑦 (𝐽)
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑂𝑟𝑔𝑎𝑛 (𝐾𝑔)

𝐷(𝐺𝑦) =

𝐴𝑖𝑛𝑗 (𝐺𝐵𝑞)∗(1−𝐿𝑆𝐹)∗50
𝑊(𝑘𝑔)

𝐷(𝐺𝑦)𝑁𝑜𝑟𝑚𝑎𝑙= 𝐴𝑖𝑛𝑗 (𝐺𝐵𝑞) ∗ 𝑚

(1−𝐿𝑆𝐹)∗50
𝑛𝑜𝑟𝑚𝑎𝑙 +𝑇𝐿𝑅∗𝑚𝑡𝑢𝑚𝑜𝑟

𝐷(𝐺𝑦) 𝑇𝑢𝑚𝑜𝑟 = 𝑇𝐿𝑅 ∗ 𝐷(𝐺𝑦)𝑁𝑜𝑟𝑚𝑎𝑙

38

39

40

41

Here, Ainj is the injected activity, LSF is the lung shunt fraction and W is the weight of the
vascularized hepatic volume, TLR is the tumor to liver ratio, mnormal is the mass of the normal liver
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compartment, mtumor is the mass of the tumor compartment, DNormal is the radiation absorbed dose
by the normal/healthy liver and DTumor is the absorbed dose by tumorous liver tissues.

Figure 45: Human body models of older (left) and newer version (right) for standard organ sizes
(81).
The dose reported by these methods is, however, the mean absorbed dose in normal or
tumor volumes based on the assumption of a uniform activity distribution within the source
volumes (32). In RMT treatment however, the microspheres are deposited in the liver as a number
of discrete clusters rather than as point sources that are homogeneously distributed throughout the
tumor or healthy liver. This irregular clustering of microspheres produces a highly heterogeneous
radiation dose distribution pattern. As a result errors in the order of 30-100% have been reported
from the assumption of uniform distribution (30). Thus, non-uniform dosimetry methods that
represent actual 90Y microsphere distribution in SPECT/CT or PET/CT is essential as the mean
absorbed dose to an organ calculated by the MIRD formula doesn’t provide enough information to
predict the potential biological effects as well as treatment efficacy. Regional or voxel-based
dosimetry that addresses the nonuniform 90Y microsphere distribution is thus required. SPECTbased dosimetry is more acceptable than PET since most therapeutic radionuclides are not positron

77

emitters, but rather single photon emitters suitable for SPECT imaging. As previously explained
in chapter 2 studies have shown the feasibility of 90Y PET/CT imaging dosimetry estimation.
Voxel based dosimetry is the calculation of radiation absorbed dose to tissue regions with
dimensions ranging from a few centimeters to hundreds of microns (78). Voxel based dosimetry
has various approaches. One of the simplest approaches is the assumption that the emitted energy
is completely absorbed locally, at the voxel where it is emitted (82). Other approaches that don’t
require such assumption are the voxel S value method (Fig. 46), the dose point kernel and the Monte
Carlo radiation transport methods (78).
(128,128,128)

(0,0,0)
Source
voxel

Target
voxel
(i, j, k)

(i+1, j+1, k)

Figure 46: Illustration of voxel dosimetry

The Voxel S value method and dose point kernel are considered to be better choices than
the simplified method mentioned that assumes complete local absorption and as well as the
computer intensive and time consuming method based on Monte Carlo radiation transport (32). S
value is ‘the mean absorbed dose to a target organ per radioactive decay in a source organ,
mGy/MBq s’ (83). The product of source organ cumulative activity and the corresponding S value
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gives the target organ dose. MIRD S values calculated from Monte Carlo simulation are widely
used for dose calculation (82). The disadvantages to using these MIRD S values are the assumption
of uniform activity distribution in source organs and uniform deposition in target organ, use of
anatomic models for organ sizes and shapes (Fig 44), and lack of S values for tumor volumes
(82,83). To compensate for these limitations of the MIRD formalism, Franquiz et al. and Bolch et
al. (78,83) have developed a method that calculates beta S values between the source and target
voxel centroids that will help determine dose distribution at the maximal experimental resolution.
This method helps to determine S values for a set of all possible combinations of cubical and noncubical pixel edges used in SPECT or PET studies.
7.2 Materials and Methods
The voxel S-value method was used to estimate 3D radiation absorbed dose in 90Y SPECT/CT and
PET/CT images. Cubical voxel S values for the pixel size of 4.664 mm were determined using
linear interpolation from 3 and 6 mm pixel sizes estimated in Franquiz et al. and Bolch et al. (83)
using Eqn. 42;
𝑚𝐺𝑦

𝑆

𝑆

𝑆 (𝑀𝐵𝑞𝑠) = 𝑆1 + (𝑉 − 𝑉1 )(𝑉2−−𝑉1 )
2

𝑚𝐺𝑦

1

𝑚𝐺𝑦

𝑆 (𝑀𝐵𝑞 ) = 𝑆 (𝑀𝐵𝑞𝑠) × 𝑇𝑒𝑓𝑓_ℎ𝑎𝑙𝑓𝑙𝑖𝑓𝑒 (𝑠)
1
𝑇𝑒𝑓𝑓_ℎ𝑎𝑙𝑓𝑙𝑖𝑓𝑒

1

=𝑇

𝑏𝑖𝑜_ℎ𝑎𝑙𝑓𝑙𝑖𝑓𝑒

+

1
𝑇𝑝ℎ𝑦_ℎ𝑎𝑙𝑓𝑙𝑖𝑓𝑒

42
43
44

S1, S and S2 are the S values and V1, V and V2 are the volumes for the 3, 4.66 and 6mm pixel sizes
respectively, Teff_halflife if the effective half-life calculated from the biological half-life, Tbio_halflife
and physical half-life, Tphy_halflife, which are 49 years and 2.67 days respectively for 90Y. A similar
method was followed for calculating the S values for 99mTc SPECT/CT images. Figure 47 shows
that fractions of absorbed dose for electrons (beta particles) starts out big but there is a rapid
decrease in dose fraction after the electron range, which is 11mm for 90Y. After this point the
fractional dose in the range of 10-7 and 10-8 is mainly due to the bremsstrahlung photons. For
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99m

Tc, which is a gamma emitter, although higher dose fraction is seen within the 11mm range

there is a substantial dose contribution well beyond this range demanding the inclusion of far
more number of surrounding voxels in dose calculations. S values were generated for the positive
(first) octant only due to the symmetry of values in the negative octants.

Figure 47: Plots of absorbed dose fraction for electrons (left) and photons of a 6mm voxel on
edge (78).
Absorbed dose per voxel was estimated by convolution of the cumulative activity images with the
corresponding voxel S values, implemented using a MATLAB® algorithm (Eqn. 45) based on the
MIRD Pamphlet No. 17 (78).
𝐷𝑇 = Ã ⊗ 𝑆 = Ã𝑆1 ×𝑆𝑇←𝑆1 + Ã𝑆2 × 𝑆𝑇←𝑆2 + Ã𝑆3 × 𝑆𝑇←𝑆3 …
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DT is the absorbed dose at the target voxel (mGy), Ã (MBq) is the time-integrated cumulative
activity in a voxel from sequential imaging, ⊗ is the 3D convolution and S is the voxel S-value
(mGy/MBq) for each associated distance from the target voxel. For the 90Y-microshpere dosimetry
calculation, cumulative activity isn’t used due to the permanent implant of the microsphere where
there is no elimination, redistribution and washout phases of the radiopharmaceutical. Thus a
single imaging performed after microsphere administration is used for dosimetry estimation where
sequential imaging after day 1 isn’t usually performed (84). Thus in Eq. (45) activity from a single
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scan, A, is used instead of Ã at each voxel. In addition to our method, we estimated dosimetry using
the MIRD partition model (Eq.39-40) and using S values generated by a direct MC method for a
4.8mm edge voxel (referred to here as MC method for ease of understanding) as reported elsewhere
(85).
Dose-volume histogram (DVH) is a display of 3D dose distribution in relation to the target
volume and normal structure [Fig. 48(A)]. It is a direct and informative method of assessing a
treatment plan via representing the frequency distribution (histogram) of doses over a given volume
(target) for each voxel in 3D. DVH provides easily interpretable 2D graphs from the vast 3D
radiation dose information. There are two types of DVH: Differential DVH (dDVH) where the
percentage or absolute volume receiving dose in a corresponding dose bin is calculated, and
cumulative DVH (cDVH) where the percentage or absolute volume receiving greater than or equal
to the value in a corresponding dose bin is calculated. Generation of DVH is only possible for a
voxel based dosimetry thus the MIRD method can’t provide the details of dosimetry estimation
[Fig. 48(B)]. cDVHs and Isodose curves (Eqn. 46) were generated for the tumor and healthy liver
VOIs and fused with the SPECT/CT dose map images using a third-party software for a 3dimensional display called 3DSLICER, an open source software for medical image processing and
3D visualization (86).
𝑖𝑠𝑜𝑑𝑜𝑠𝑒 (𝑥, 𝑦, 𝑧) =

𝐷𝑜𝑠𝑒 (𝑥,𝑦,𝑧)
𝑀𝑎𝑥_𝐷𝑜𝑠𝑒(𝑥,𝑦,𝑧)
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×100%
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A)

B)

Figure 48: Display of details provided by DVH (A) and its implementation from activity and dose
map images (B) where this implementation isn’t possible for the MIRD method highlighted.

7.3 Results and Discussion
Generated voxel S-values are shown in Fig. 49 for 90Y. Figure 49 shows plots of voxel S
values for different distances within the beta range for 90Y and 99mTc. The plots resemble Fig. 47
of values generated by direct MC simulation. The mean absorbed doses for the tumor and healthy
liver from 90Y microsphere SPECT/CT images were 62.6 ± 20.2 (range: 38.4 to 117.2 Gy) and 12.4
±4.7 (range: 6 to 23.7 Gy) respectively using our method.

Figure 49: S values for various voxel sizes and interpolated results for 4.664mm voxel size at
different source coordinates.
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Figure 50: Calculated voxel S values for 90Y (left) and 99mTc (right) within the beta range.
The mean absorbed doses in tumor and liver volumes calculated by the three methods:
proposed (our method), MC (voxel size = 4.8mm) and MIRD partition model are shown in Fig. 51.
For the MIRD method mass of tumor and liver were calculated using the segmented volumes and
density of a soft tissue (1.03 g/cm3); mass (g) = density (g/cm3) x volume (cm3). Figure 52
summarizes the distribution of calculated absorbed doses in the tumor and liver volumes by the
three methods. Overall higher doses are found by our method while the MC method gave the
smallest estimated doses in both volumes.
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Figure 51: Bar plots of tumor (upper) and liver (lower) mean absorbed doses calculated by the
three methods.
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Figure 52: Box-Whisker plots of the calculated dose distribution in the tumor (left) and liver
(volumes).
Figure 53 shows the cDVH for all patients in the tumor and liver VOIs. The tumor cDVH
showed similar dose absorption scheme for all patients [Fig 53(A)] except for patient 3 who
showed the highest dose per tissue volume. The isodose curves fused on the patient CT scan
showed a much localized treatment dosimetry for a relatively low administered dose (558.7 MBq)
with maximum absorbed dose of 500 Gy [Fig. 53(B)]. The cDVH for the liver VOIs showed that
absorbed doses are within the maximum tolerated dose of 40 Gy by a liver tissue (87).
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A)

B)

C)

Figure 53: cDVH of tumor (A), fused isodose lines and CT scan for patient 3 (B) and cDVH of
liver VOIs for all patients(C).
Dose distribution for the pre and post-treatment SPECT/CT images for patients who
showed equal, two and three times of TRLs in their 99mTc-MAA scan than the 90Y microsphere
uptake (Table 13) is shown in Fig. 54. The figure shows the percent distributions in accordance to
the maximum absorbed dose. The maximum 90Y microsphere uptake were 88, 142 and 1161 Gy
for patient 9, 13 and 17 respectively.
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Table 15: Tumor volumes and TLRs for pre and post-treatment SPECT/CT images.
Pat

Tumor volume (ml)
99m

Tc-MAA

TLR

90

Y microsphere

99m

Tc-MAA

90

Y microsphere

Pat 9

757

865

2.7

2.6

Pat 13

725

1008

10.2

5.3

Pat 17

271

403

14.7

5.0

Figure 54: Fused isodose curves with the SPECT/CT of 99mTc-MAA (left) and 90Y microsphere
(right).
Comparison of the dose distribution between images corrected for collimator blur using
the developed method and those uncorrected showed a significant difference in the isodose curves
whilst the overall difference in the cDVH per tissue volume is small, example shown in Fig. 55.
Figure 56 shows a similar comparison for the same patient where the S values for 4.8mm were
used for the method referred as the MC method. The dose distributions from both methods are
similar but the major difference in the cDVH illustrated the actual absorbed doses per tissue
volume are significantly different.
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Figure 55: Dose distribution between 90Y microsphere images before and after correction for
collimator detector effect (left) and difference in cDVH (right).

Figure 56: Comparison of dose distribution calculated using developed and the MC method on
90
Y microsphere SPECT/CT images (left) and the resulting difference in cDVH (right).
Figure 57 demonstrates the relationship between the administered activities and absorbed
doses, there is a weak correlation with tumor absorbed dose (r = 0.5, p > 0.05) but a strong
correlation with healthy liver absorbed dose (r = 0.8, p < 0.05). From the figure, it is observed that
one patient appears as an outlier. Although the patient shouldn’t be considered an outlier, since the
administered activity (x-axis) is substantially higher than the rest of the patients, i.e. the higher
absorbed dose in the liver and the tumor is valid considering the amount of administered activity.
For the sake of completeness, we excluded this patient and analyzed the relationship between the
administered activity and the absorbed doses in tumor and liver volumes. The result of this analysis
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gave a linear relationship between administered activity and liver dose (r = 0.52, p = 0.1) but the
higher p value suggests that the correlation is not dependable as the sample size is small. And no
correlation between the administered activity and tumor absorbed dose was found (r = 0.21, p =
0.54).
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Figure 57: Correlation of administered activity with healthy liver and tumor absorbed doses.
Accurate dosimetry requires accurate voxel S values for the image voxel size. For our
work, we used linear interpolation to estimate the voxel S values appropriate for the SPECT images.
The most accurate method of estimating a voxel S value is using a direct Monte Carlo method for
the exact voxel sizes of images at hand. Although using Monte Carlo machine isn’t part of this
dissertation, we compared dosimetry results between our developed method and S values generated
using the MC method for a voxel size of 4.8mm, closer to our voxel size (4.66mm). For as low as
less than 0.2mm difference in voxel edge sizes between the two methods, the reported mean dose
values in the VOIs was substantial with the MC method giving smaller values. For 90Y, with mean
beta particles range of 2.5mm, almost half the distance between the centroid of two voxels
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(4.66mm), taking a large voxel edge size (4.8mm) undermines the effect of the dose from beta
particles that traveled shorter distances, giving an overall smaller dose estimate at the target voxels,
i.e. undermining the effect of the immediate neighborhood voxel. Although there is no gold
standard for validating dosimetry estimates, the MIRD method is considered the standard method
of clinical dosimetry (88). Results of mean dosimetry from our method and the MIRD partition
model based estimate is comparable for most of the patients. It should be emphasized here that the
parameters used, such as TRL, tumor and liver volumes were similar in both methods in addition
to the fact that there is only one tumor volume per patient. But the result might be different if the
parameters were estimated for individual tumors as the TLR is dependent on overall counts/activity
within a volume.
For the images uncorrected and corrected for spatial resolution recovery, the mean dose
estimate within target VOIs is higher for the latter one as the spatial resolution recovery is based
on deconvolution giving a more heterogeneous isodose distribution.
Comparing the pre and post-treatment dosimetry, for the small cohort patient data we
studied we found no associations between TLRs and dose distributions. The expectation of equal
TLR predicted from the

99m

Tc-MAA study and that calculated from 90Y microsphere uptake is

taken as a guarantee of treatment success (10). But this expectation doesn’t put into consideration
the actual dose distribution between the two images. A study by Wondergem et al. (72) stated that
99m

Tc-MAA poorly predicts the distribution of 90Y resin microspheres. The authors used the Blan-

Altman analysis to compare the distribution of the two activities. The study included patients with
catheter positions similar in both planning and treatment procedure as well as those where the
positions of the catheter was different in the two sessions. The authors found that the positions of
the catheter tip during administrations significantly influences the disagreements and concluded
that

Tc-MAA doesn’t accurately predict final 90Y microsphere distribution. In our study, we

99m
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compared the two procedures in terms of TRL as well as activity distribution. Our conclusion is
that TLR shouldn’t necessarily be the one parameter to evaluate the predictive accuracy of

99m

Tc-

MAA on the actual 90Y microsphere treatment outcome.
We found no correlation between tumor dosimetry and administered activity while the liver
dosimetry increased with an increase in the administered dose. This finding is justifiable as the
administered activity for

90

Y resin (SIR-Spheres) microspheres treatment is based on the body

surface area (BSA) method where the prescribed activity is adjusted based on the extent of tumor
involvement in the liver and size of the patient (Eqn. 11). Thus, an increase in the administered
activity may not result in an increased tumor uptake but a higher activity in the overall liver region.
7.4 Conclusion
A dosimetry algorithm that considers the non-uniform 90Y microsphere distribution has
been developed. The algorithm provides a 3D estimation of full radiation dose distribution within
liver and the surrounding organs. The algorithm improves reproducibility of radiation dose
calculation and solely depends on the specific patient image as opposed to relying on a standard
human organ size which doesn’t reflect individual patient biokinetic and response.
Summary, Limitations and Future work
90

Y is pure beta emitter which makes it an effective radionuclide for radioimmunotherapy

of cancer increasing the radiation dose to tumor from the high energy beta particles. However, due
to their short range, these particles can’t be directly detected outside of the patient body for
quantitative imaging. Instead secondary photons emitted as the result of the interaction between the
beta particles and tissue are detected. SPECT/CT imaging utilizes bremsstrahlung photons emitted
as a result of this interaction while PET/CT uses the small portion of annihilation events for
assessing radionuclide distribution. 90Y bremsstrahlung has a continuous energy spectrum resulting
in scattered and septal penetration of photons during detection causing very poor image quality.

90

On the other hand, the very small annihilation events for 90Y PET/CT imaging has strong presence
of random and scattered coincidences from the associated bremsstrahlung photons.
The first goal of this dissertation has been to employ a more realistic technique to improve
90

the quantitative quality of

Y bremsstrahlung SPECT/CT and PET/CT images for dosimetry

purposes. The post-reconstruction quantitative image improvement technique corrects image
degradation due to collimator-detector response. The method considers the types of noises present
in nuclear medicine imaging making it suitable for both SPECT and PET modalities. The only
factor that interchanges between the modalities is the FWHM. Attenuation and scatter correction
were performed using the manufacturers’ software provided for each modality. The challenges for
our method were image degradation due to object scatter, septal penetration and backscatter. These
shortcomings limit the improvement in 90Y bremsstrahlung SPECT/CT imaging. However, these
effects are not a major concern in PET/CT imaging due to the coincidence detection mechanism
and the algorithm employed for attenuation and scatter correction. The challenge with PET/CT
imaging is the actual representation of patient administered dose due to the reliance of the image
accuracy on the activity concentration under study. Despite these challenges, validation of the
developed algorithm using phantom studies and clinical images has shown meaningful quantitative
improvement which allows accurate quantification of total administered dose to a patient for
treatment outcome prediction. Future quantitative improvement of 90Y bremsstrahlung with ease of
clinical application that includes compensation for the scatter, septal penetration and backscatter
will provide complete correction of the image degrading factors. A future 90Y PECT/CT study with
similar activity concentration as patients recruited for RMT should be performed to represent actual
count statistics.
The second objective of the dissertation focused on comparing the uptake distribution
between pre-treatment

99m

Tc-MAA and post-treatment
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90

Y microsphere SPECT/CT images.

Accurate pre-treatment estimation of microsphere distribution within the tumor and healthy liver
is critical for the success of RMT. Very small and diffused tumors that cannot be delineated on CT
images can be identified using the functional SPECT images. Due to this benefit, our comparison
of uptake between the two images was based on tumors delineated using the SPECT images.
However, a tumor delineation technique that considers the non-uniform microspheres distribution
within a tumor was a challenge. In addition, proper matching of the two pre and post-treatment
SPECT/CT images in three dimensions was also investigated. Correlation analysis of the uptake
distribution between the two images was based on cumulative tumor volumes. This comparison
gives the entire activity distribution within the liver. Individual tumor comparison of pre and posttreatment uptake would provide a more detailed analysis of the study which would require a tumor
segmentation on the CT scan by a radiologist.
In the final part of this dissertation, we developed a 3D algorithm for estimating radiation
absorbed dose in tumor and liver VOIs. The method employs the voxel S-value method to calculate
cumulated dose in each voxel from surrounding voxels giving absorbed dose per tissue volume. A
future study could determine the correlation between tumor and liver dose estimates obtained from
90Y microspheres bremsstrahlung SPECT/CT imaging with tumor response and liver toxicity. This
correlation might help in future treatment planning by setting a linear relationship between
administered dose and tumor response. However, tumor response depends on many factors, such
as tumor size, vascularity (blood supply), and presence of necrotic core which are different from
patient to patient. Thus, future research should also consider the patient specific factors for
treatment planning. Increasing patient population by incorporating those with higher LSF in the
future study will enhance the dosimetry result by giving a complete perspective of treatment
response to absorbed dose. This would require collecting extra patient data such as follow up
studies. For patients who undergo multiple RMT, analysis of the change in tumor vasculature
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should also be part of the study as the change might contribute to the overall activity distribution
within the liver.
Overall Conclusion
Nuclear medicine quantitative methods in

90

Y bremsstrahlung SPECT/CT and PET/CT

imaging were investigated and evaluated for improved quantitation and dosimetry in RMT. The
proposed maximum likelihood iterative spatial resolution algorithm corrects for detector response
and Poisson statistical error using the Bayes’ theorem. Optimal iteration number (6 iteration) of the
algorithm was found from phantom studies and the algorithm was applied on patient

90

Y

microsphere SPECT/CT images. Improvement in contrast recovery coefficients was achieved both
in phantom and patient images. Methods for estimation of calibration factor were designed and
implemented for activity estimation from patient and phantom images. We found that the
calibration factor estimated using counts within liver VOIs gave the best results. Appropriate image
co-registration methods for proper alignment of

99m

90

Tc-MAA and

Y microsphere SPECT/CT

images were investigated and determined. Correlation of uptake distribution between pre and posttreatment RMT were studied and correlation was found between the

99m

Tc-MAA and

90

Y

microsphere SPECT/CT images. An algorithm for radiation absorbed dose estimation was
developed. The algorithm considers the non-uniform 90Y microsphere distribution in RMT and
estimates dose delivered in tissue per volume at a voxel level. The method was implemented in
patient 90Y microsphere SPECT/CT images and isodose distributions were identified and aligned
with the anatomical locations. In addition, dose volume histogram was generated for liver and
tumor VOIs. For the moderate sample size (12 patients) studied, we found no significant similarity
between the results of TRL and dose distribution on 99mTc-MAA and 90Y microsphere SPECT/CT
images. This result highlights the need for more than one parameter to justify the predictive
accuracy of

99m

Tc-MAA for subsequent treatment outcome of
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90

Y microspheres. Correlation

between administered activity and absorbed doses in tumor and healthy liver was studied. The
absorbed dose in tumors didn’t show a linear relationship with the administered activity, while

healthy liver absorbed dose increased with administered activity.
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